Archive for July, 2020

Liz Satterfield has a ritual for every time she returns home after leaving the house. Diagnosed with metastatic breast cancer in 2016, the Kirkland, Washington resident recently learned that the cancer that had spread to her brain in 2018 was still growing. Throughout the pandemic, shes had to visit the hospital at least once every three weeks, often more frequently, for treatments to control her disease.

I have a pair of shoes in a paper bag that I keep in the trunk of my car or a rack in the garage. I only wear those shoes when Im going in to get treatment, she says. When I come home, I strip in the garage and put everything right in the wash. I dont enter the house with anything that I was wearing at the cancer center. Its the way Im able to control what I can control in this situation, and gave my partner and me some peace of mind.

While COVID-19 has upended everyones life, the novel coronavirus impact on cancer patients is especially disruptive. Any infectious disease that taxes the immune system is high on their must-avoid listespecially for those getting chemotherapy or radiation treatments, both of which can weaken natural defenses. So that leaves cancer patients caught in the middle of two terrifying diseases.

Nearly 17 million people in the U.S. are living with cancer, many of whom, like Satterfield, are currently being treated for their disease, and forced to make these difficult calculations weighing their risk of cancer against their risk of getting COVID-19. Studies of cancer patients who become infected suggest that their death rate is higherranging from 13% to 28%than those without cancer (though these numbers continue to change as more data become available).

That risk could have a lasting impact on cancer rates and deaths in coming years. Between existing cancer patients who are concerned about the risk of COVID-19 and either delay or skip treatments, and those who have not yet been diagnosed but are reluctant to see their doctor for possible cancer symptoms, experts say both death rates and new cases may creep up. There have been people who are scared to death to even come near the cancer center, says Dr. Leslie Busby, a partner at Rocky Mountain Cancer Centers.

A crude forecast of how the pandemic might affect deaths from just breast and colon cancers alone conducted by researchers at the National Cancer Institute (NCI) predicts 10,000 additional deaths from these two cancers on top of an expected 1 million over the next decade, based on the assumption that screenings are stopped for only six months. That model does not account for people who have not yet been diagnosed and are delaying seeing their doctorsand as a result, may not be diagnosed until their cancers are more advanced and harder to treat. We dont know what the level of disruption to care is going to be, but I think it has already been quite significant, and will last a while longer, says Dr. Ned Sharpless, director of the NCI, who commissioned the prediction.

He notes that increases in incidence and deaths from cancer due to COVID-19 may also be hidden, complicated by the fact that incidence, for example, may even dip for a while if fewer people are getting screening and fewer cancers are actually detected. Mortality may also be confounded by the fact that most cancer deaths are among older patients, and older patients are also at higher risk of dying from COVID-19 complications, so the pandemic could cause total cancer deaths to actually decrease tempoerarily.

Given those confounders, and the fact that many cancers take years to develop, it wont be clear exactly how COVID-19 has affected cancer rates and deaths for many years yet.

When you think of cancer care, there is very little that is elective, says Dr. Robert Keenan, chief medical officer and vice president of quality at Moffitt Cancer Center in Tampa, Fl. Patients get chemotherapy as an intravenous infusion, which needs to be dosed and administered under medical care, and radiation treatments require calibrated doses from certified technicians in hospitals. And once patients have started chemotherapy or radiation regimens, they usually undergo treatment for several weeks, with each cycle building on the last to give them the best chance of wearing the cancer down and stopping malignant cells from growing and spreading.

As the pandemic began to surge, cancer doctors typically evaluated each of their patients to decide whether they needed to come in for their treatments or whether they could safely put off the chemotherapy infusion or radiation session for a week or more. Nancy Fleming, a former hospital pharmacist who was diagnosed with small cell lung cancer in 2019 after surviving breast cancer in 2003, receives an infusion of an immunotherapy drug once a month at the Dana Farber Cancer Institute in Boston, Mass. When cases of COVID-19 surged in Boston in April, her oncologist, Dr. Jacob Sands, suggested she put off one of her infusions by a week. He says he made these types of decisions on a case-by-case basis, depending on how well each individual patient was doing and how well-controlled their cancer was. For somebody who has ongoing disease control, where everything is stable, and they had been on therapy for more than a year, those were cases where we would discuss delaying treatment by a week, two weeks or even three weeks, Sands says.

Convincing them to continue their treatments wasnt easy, however. There was a lot of virtual and telephonic hand-holding, says Keenan. We tried to put in place measures to create an environment that let patients know that [the cancer center] was as safe a place as any to come in for their treatment. At many hospitals and cancer centers, patients and staff have been screening patients and staff for fever and COVID-19 symptoms, and many restricted visitors from coming with the patients for their treatments. Any care that could be provided virtually was moved to video or telemedicine, which cut down on the density of people. At Moffitt, Keenan says, clinic visits dropped by 40% to 50%, and patient appointments were scheduled to avoid pile ups waiting rooms. At Dana Farber, Sands says Patients were essentially able to get right into a private room when they showed up and we were able to completely isolate people so they were not sitting next to each other in the waiting room.

Such cues are critical to putting cancer patients at ease, agrees Busby, who asked non-essential staff to work from home. These practices helped to both lower the risk of spreading COVID-19 and sent signals to our patients that we were doing the best we can to protect their health, he says. Discussing these precautions helped to convince some wary patients to continue their treatments.

One such policy, however, was harder for patients to accept. Many cancer centers stopped allowing visitors to come with patients during their treatment appointments, which can stretch for several hours since the chemotherapy infusions themselves typically take at least 30 minutes. Its such a comfort to have family there, says Fleming. When you are a patient, when you are ill, its sometimes hard for you to absorb everything you are hearing. Its always good to have an advocate with you.

For breast cancer patients, there were other options as well. At the University of North Carolina Lineberger Comprehensive Cancer Center, Dr. Lisa Carey says the pandemic changed the therapies she offered her patients. At the beginning of the pandemic, for the patients whose cancers were hormone sensitive, I put them on anti-estrogen [pills] so we could tread water and keep an eye on the tumor for a couple months, while we waited for the [COVID-19] dust to settle before exposing them to an unknown level of danger of coming into the hospital for chemotherapy infusions, she says. The oral treatment, normally given before or with chemotherapy for maximum effectiveness, allowed the patients to treat their cancer and not compromise their care while avoiding exposure to the risks of COVID-19 in the hospital. The truth is, those things we did to protect them seemed to work, Carey says.

Protecting patients from getting exposed to the virus also guides some of her decisions around how to provide chemotherapy. If I have a choice between a [chemotherapy] drug that is given every week and a similar one that is given every three weeks, I now routinely use the one thats given every three weeks, she says. Even if there are a few more side effects, if it reduces the number of times a patient has to come in, then this is a conversation Im having with them.

Similar adjustments are possible for radiation treatment in some cases. Normally, radiation therapy is broken up into smaller, daily fractions in order to preserve the healthy tissue around cancers from the toxic effects of single blast. For breast cancer patients, recent, albeit early studies that followed patients for five years, suggested that significantly shorter courses of treatmentgiven over five days compared to 30, for examplecould be equally as effective in controlling the cancer. Typically we wouldnt embrace [such early results] in daily practice as quickly as we did except for the pandemic, says Dr. Reshma Jagsi, deputy chair of radiation oncology at the University of Michigan. But some patients were willing to take the risk of not having long term evidence on the safety and trust the five year data which was certainly compelling and intriguing.

For the most part, cancer patients have understood the importance of continuing their treatment and of balancing their risk of cancer against their risk of getting COVID-19. In fact, says Busby, its not so much our patients we worry about but the patients who are not ours yet. Most hospitals canceled routine cancer screening appointments for things like mammograms and colonoscopies, which are essential for detecting cancer early. And many people who might have potential cancer symptoms and arent diagnosed yet, arent going to the doctor because of COVID-19 fears. If thats the caseand only data on cancer rates in the coming months and years will provide the answerits possible that both the number of new cancer cases and their severity will increase as a result of the pandemic.

My concern is for the patients who have not yet been diagnosed with cancer; for those patients who delayed their screening; for patients who put off being examined for certain symptoms, says Jagsi. Those patients will be diagnosed at later stages and I do have great concern there that will change cancer-related treatment outcomes. In recent years, advances in screening have helped doctors more regularly diagnose patients at earlier stages where their disease is still treatable and curable, Jagsi notes. I fear that some COVID-19-related delays may compromise some of the advances we have seen.

How deeply COVID-19 will cut into those gains wont be clear until more data on new cancer cases becomes available in coming months. But most experts agree that its hard to imagine that the pandemic would contribute to a better situation; its going to have to be worse, says Carey.

In the meantime, patients are learning to accept the adjustments they need to make to ensure their treatments continue with as little disruption and in the safest way possible. Satterfield has had two COVID-19 tests because the chemotherapy she receives gives her a runny nose, cough and diarrheaall symptoms of COVID-19 that are flagged when she is screened before entering the cancer center for her treatments. But shes okay with that, and understands why its needed. For her, the most challenging part is emotional. With any terminal illness, its thereI think, is this the way the world is going to be when I die? Is this how I see the end of my life? But Im feeling better than I have in recent memory. As much as my health status doesnt sound great, I feel great. And Im thankful for that.

Thank you! For your security, we've sent a confirmation email to the address you entered. Click the link to confirm your subscription and begin receiving our newsletters. If you don't get the confirmation within 10 minutes, please check your spam folder.

Contact us at editors@time.com.

See the original post here:
Coronavirus Could Upend Cancer Trends in the U.S. - TIME

The report Bone Marrow Transplant Rejection Treatment Market Research Report 2015-2026 provides an in-depth analysis of the global Bone Marrow Transplant Rejection Treatment market across top key companies, products, and Applications. The research report provides an inclusive analysis of major industry drivers, restraints, and their impact on market growth during the forecast period.

The Bone Marrow Transplant Rejection Treatment Market Report covers the manufacturers data, pricing, revenue, gross profit, business distribution, demand, market size & growth forecast, etc. This information helps the consumer know about the competitors better. This Bone Marrow Transplant Rejection Treatment Market report also covers all the regions and countries of the world, which shows a regional development status, including market size & share, sales data, volume and value, as well as price data

Get Exclusive Sample copy on Bone Marrow Transplant Rejection Treatment Market is available at https://inforgrowth.com/sample-request/6303015/bone-marrow-transplant-rejection-treatment-market

Bone Marrow Transplant Rejection Treatment Market 2020-2026: Segmentation

The Bone Marrow Transplant Rejection Treatment market report covers major market players like Bellicum Pharmaceuticals, Inc., Bio-Cancer Treatment International Limited, Biogen Inc, Boryung Pharmaceutical Co., Ltd., Bristol-Myers Squibb Company, Cantex Pharmaceuticals, Inc., Capricor Therapeutics, Inc., Cell Source, Inc., Cell2B S.A., CellECT Bio, Inc., Cleveland BioLabs, Inc., Compugen Ltd., Cynata Therapeutics Limited, Cytodyn Inc., Dompe Farmaceutici S.p.A., Dr. Falk Pharma GmbH, Escape Therapeutics, Inc., F. Hoffmann-La Roche Ltd., Fate Therapeutics, Inc., Generon (Shanghai) Corporation Ltd.

Bone Marrow Transplant Rejection Treatment Market is segmented as below:

By Product Type: Azathioprine, Adrenocorticotropic Hormone, Cyclophosphamide, Cyclosporine A, Others

Breakup by Application:Hospital, Clinic, Others

Impact of COVID-19:Bone Marrow Transplant Rejection TreatmentMarket report analyses the impact of Coronavirus (COVID-19) on the Bone Marrow Transplant Rejection Treatmentindustry.Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 180+ countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Bone Marrow Transplant Rejection Treatmentmarket in 2020.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; emergency declared in many countries; massive slowing of the supply chain; stock market unpredictability; falling business assurance, growing panic among the population, and uncertainty about future.

COVID-19 can affect the global economy in 3 main ways: by directly affecting production and demand, by creating supply chain and market disturbance, and by its financial impact on firms and financial markets.

Download the Sample ToC and understand the COVID19 impact and be smart in redefining business strategies. https://inforgrowth.com/CovidImpact-Request/6303015/bone-marrow-transplant-rejection-treatment-market

Global Bone Marrow Transplant Rejection TreatmentMarket Report Answers Below Queries:

To know about the global trends impacting the future of market research, contact at: https://inforgrowth.com/enquiry/6303015/bone-marrow-transplant-rejection-treatment-market

Purpose to Purchase This Report:

Get Special Discount UP TO 50% for this Report:https://inforgrowth.com/discount/6303015/bone-marrow-transplant-rejection-treatment-market

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: US: +1-909-329-2808UK: +44 (203) 743 1898

Here is the original post:
Top key Players Impacting the Growth of the Bone Marrow Transplant Rejection Treatment Market 2020 | COVID19 Impact Analysis Bellicum Pharmaceuticals,...

There are dozens of potential coronavirus treatments in development or undergoing tests.

One intravenous (IV) treatment touted by Dr. Anthony Fauci of the White House coronavirus task force is remdesivir, made by Gilead Sciences.

Gilead has now announced pricing for its drug: $520 per vial, which adds up to $3,120 per patient for a six vial course of treatment.

The price to those "outside of private insurance" will be $390 per vial, Gilead says, or $2,340.

According to Reuters:

Analysts at Royal Bank of Canada said they saw revenue potential of $2.3 billion from the drug in 2020, helping offset more than $1 billion in development and distribution costs.

In contrast, the malaria drug hydroxychloroquine can cost pennies per dose and is being studied not only to treat coronavirus, but also to prevent it.

A media campaign controversialized hydroxycholorquine after President Trump repeatedly said the drug could be a game changer if it proves to be effective against coronavirus.

Studies have produced mixed results when it comes to both hydroxycholorquine and remdesivir.

A third drug, dexamethasone, is also being tested to use against coronavirus, as are numerous other medicines.

More results of various studies are expected by summer's end.

Read more by clicking the link here.

https://www.medscape.com/viewarticle/933097?src=mk

Fight improper government surveillance. Support Attkisson v. DOJ and FBI over the government computer intrusions of Attkisson's work while she was a CBS News investigative correspondent. Visit the Attkisson Fourth Amendment Litigation Fund. Click here.

Read more:
The high cost of the IV drug remdesivir for coronavirus: $3120 - Sharyl Attkisson

Endometriosis Therapies market research report provides the details about Industry Chain structure, Market Competition, Market Size and Share, SWOT Analysis, Technology, Cost, Raw Materials, Consumer Preference, Development and Trends, Regional Forecast, Company and Profile and Product and Service.

Endometriosis Therapies market research report also gives information on the Trade Overview, Policy, Regional Market, Production Development, Sales, Regional Trade, Business Operation Data, Market Features, Investment Opportunity, Investment Calculation and other important aspect of the industry.

Request a Sample of Endometriosis Therapies Market Research Report with 121 pages and Analysis of Top Key Players at https://www.insidemarketreports.com/sample-request/10/378567/Endometriosis-Therapies

Our industry professionals are working reluctantly to understand, assemble and timely deliver assessment on impact of COVID-19 disaster on many corporations and their clients to help them in taking excellent business decisions. We acknowledge everyone who is doing their part in this financial and healthcare crisis.

The main objectives of the research report elaborate the overall market overview on Endometriosis Therapies market dynamics, historic volume and value, robust market methodology, current and future trends, Porters Five Forces Analysis, upstream and downstream industry chain, new technological development, cost structure, government policies and regulations, etc. Major companies, company overview, financial data, products and services, strategy analysis, key developments market competition, industry competition structure analysis, SWOT Analysis, etc.

Further Endometriosis Therapies market research report provides regional marketanalysis with production, sales, trade and regional forecast. it also provides market investment plan like product features, price trend analysis, channel features, purchasing features, regional and industry investment opportunity, cost and revenue calculation, economic performance evaluation etc.

The Endometriosis Therapies industry development trends and marketing channels are analyzed. Finally, the feasibility of new investment projects is assessed, and overall research conclusions offered.

Report Scope

The tunnel ventilation market has been segmented based on different types and application. In order to provide a holistic view on the market current and future market demand has been included in the report.

Major players covered in this report are AbbVie, EliLilly, AstraZeneca, Bayer, AstellasPharma, MeditrinaPharmaceuticals, Pfizer, NeurocrineBiosciences, TakedaPharmaceutical etc.

Major Points covered in this report are as below

Our research and insights help our clients in identifying compatible business partners.

Buy this report online athttps://www.insidemarketreports.com/buy-now/10/378567/Endometriosis-Therapies/single

Purchase this Report now by availing up to 40% Discount and free consultation.Offer is valid for July 2020 only.

Why Inside Market Reports:

For all your Research needs, reach out to us at:

Email: [emailprotected]

Phone: +1-617-230-0741

The rest is here:
Endometriosis Therapies Market 2020 Report Forecasts the Impact of COVID-19 Pandemic on Business and future opportunity - Owned

Transgender women should be entitled to womb transplant to enable them to have their own babies, according to a leading British surgeon.

Two years ago a woman in Brazil became the first mother to give birth to her child using a womb transplanted from a deceased donor to a woman.

It was a major breakthrough in fertility medicine when the little girl was born healthy and weighing 5.6lbs.

It comes just four years after the worlds first womb transplant baby from a live donor was born in Sweden in 2014.

Surgeon Christopher Inglefield, founder of the London Transgender Clinic, says a successful uterus implant into a trans-female is now achievable.

He says the procedure essentially identical to that of cis-women - aka females born in that gender.

Mr Inglefield, a specialist in gender confirmation surgery as well as facial and body feminisation, said: This pioneering birth is extremely important for any trans female who would like to carry her own child.

Because once the medical community accept this as a treatment for cis-women with uterine infertility, such as congenital absence of a womb, then it would be illegal to deny a trans-female who has completed her transition.

"There are clearly anatomical boundaries when it comes to trans women but these are problems that I believe can be surmounted and the transplant into a trans-female is essentially identical to that of a cis-female.

The Human Fertilisation and Embryology Authority (HFEA) confirm there are no regulations in place to prevent a trans woman who has received a uterus transplant from having IVF treatment.

And Mr Inglefield describes how a transplant would work.

He explained: "The most important step is the harvesting from the donor as great care is required to avoid damage to the arteries and veins supplying the uterus.

"The actual plumbing in is straight forward.

"The donor vessels are connected to the pelvic artery and veins which are the same in both males and females.

"With a uterus transplant in a trans-female, the neovaginal would be opened at the pelvic end to accept the donor womb.

"And the same procedure is used in a cis-female transplant with the donor uterus being attached to the native vagina.

Trans females have a much narrower pelvis than cis-women of the same height, but there would still be room for them to carry a child.

Supplemental hormones could be taken to replicate the changes that occur in the body when a woman is pregnant.

Meanwhile its highly unlikely that a trans female would give birth naturally, but would be delivered via Caesarian section in order to safeguard the child.

Other experts have also endorsed Mr Inglefields claims.

In November last year, Dr Richard Paulson, former president of the American Society for Reproductive Medicine, said there was no anatomical reason why a womb could not be successfully implanted into a transgender woman.

He added: "You could do it tomorrow. There would be additional challenges, but I dont see any obvious problem that would preclude it.

"I personally suspect there are going to be trans women who are going to want to have a uterus and will likely get the transplant.

Womb transplant surgery is being seen as a major cause for hope for those who suffer from Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome.

This is when a woman fails to develop a proper uterus and vagina yet has normal ovarian functions and normal external genitalia.

Women who have MRKH will still go on to develop breasts and pubic hair, but they will not have a menstrual cycle.

The syndrome is thought to affect around 1 in every 4,500 women.

But Mr Inglefield, who appeared in ITV's fly-on-the wall documentary Transformation Street, says the demand among trans women could be far greater.

He added: According to some estimates, the prevalence of transgender females in the UK could be as high as 1,000 per 100,000 persons, around 1 per cent of the population.

Just looking at the potential number of trans females who might seek uterine transplantation surgery and its abundantly clear it could become a vital medical service.

As it stands, trans women face a tricky pathway to motherhood, which is often achieved through surrogacy, adoption or fostering.

But those pathways are not without their own pitfalls and many would-be mothers simply long to carry their child, to be pregnant in the very real sense.

As womb transplant surgery is further improved and perfected, its vital trans women are not excluded from the conversation, at it could immeasurably improve a great many lives.

The Gender Recognition Act 2004 says that a trans female can apply for a Gender Recognition Certificate if they wish for their acquired gender to be legally recognised in the UK.

Applicants must go before a panel, documenting any treatments theyve had to change their sexual characteristics, such as hormone treatment or surgery.

They must have lived in their acquired gender for at least two years if single, or six years if married or in a civil partnership.

A spokesperson for the HFEA said: "I can confirm that to our knowledge there are currently no regulations in place which would prevent a person who has received a uterus transplant from having IVF treatment.

"The law, as it currently stands, does not require the person who is carrying a child to have obtained a GRC stating that they are female before having their fertility treatment.

And as stated in the Act the person who carries or has carried a child as a result of an embryo transfer, or artificial insemination, is considered as the mother of the child at birth."

The new test case, which has made headlines across the world, saw a 32-year-old woman born without a uterus given one taken from a 45-year-old donor who died from a brain haemorrhage.

The donor womb was implanted in a 10 hour surgery, which saw veins, arteries, ligaments and vaginal canals being connected.

And she then received fertilised eggs produced by IVF.

The birth took place in December 2017, but has only now been reported in journal The Lancet.

There have been 39 womb transplants across the world and of these, 11 babies born.

Until the Brazil transplant the surgery had failed 10 times.

The womb donor was a mum-of-three, who was in her mid-40s and died from bleeding on the brain.

Just six weeks after the surgery, the woman who received the womb started having periods.

Then, seven months later the eggs, which had been fertilised via IVF, were implanted in her womb.

Her baby was born by caesarean secion on December 15, 2017, and weighed 6lb.

Dr Dani Ejzenbery, from Hospital das Clicas in Sao Paulo, where the surgery was carried out, said: "The first uterus transplants from live donors were a medical milestone, creating the possibilty of childbirth for many infertile women with access to suitable donors and the needed medical facilities.

"However, the need for a live donor is a major limitation as donors are rare, typically being willing and eligible family members or close friends."

Imprial College London's Dr Srdjan Saso described the surgery as "extremely exciting".

The government equalities office estimates there are between 200,000 to 500,000 trans people in the UK.

Liz Armstrong, head of transplant development at NHS Blood and Transplant, said: No uterus transplant has yet been carried out in the UK.

"However if it was to go ahead, the donation and transplantation of a uterus would be carried out under the same regulatory framework in the UK as any other organ, whether from a living or deceased donor.

"The new opt out law in England, only applies to transplants which are already routinely carried out in this country specifically heart, lungs, liver, kidneys, pancreas and intestinal organs.

"It also covers certain tissue, including corneas, skin, blood vessels, bone, muscle and tendons.

"A uterus transplant would be classed as a novel transplant and would therefore only take place with the explicit permission from the donor or donors family.

"People have the option to state which routine organs they wish to donate, when recording an opt in decision on NHS Organ Donor Register.

"We would encourage everyone to speak with family and friends so they are clear on what you want to happen in the event of your death."

See original here:
Transgender women 'should be allowed womb transplants so they can have own babies' - Mirror Online

Skincare is predicting $180 billion in global spend by 2024. Thats a 30% increase from where it sits right now, but dont bother betting against it. The industry is a runaway rocket ship; it firmly pushed past makeup sales in 2018, and is now counting on multibillion dollar growth among men, who have recently discovered a wide world or products beyond lip balm and talcum powder.

This success has already birthed, or at least magnified, a number of parallel, ripple businesses, which work in tandem with skincare, and share its self-care ethos. According to market research company Datassential, this trend is best exhibited in the recent convergence of beauty and food. Emerging brands like Purely Elizabeth, Sakara, Bare Bones Broth, Coco Luxe and Kalumi best exemplify the so-called kitchen beauty renaissance, and have staked claims on the credo that looking good starts with eating better.

We applaud their efforts, and have happily recommended some of their products. But its important to remember that many of the ideas and ingredients that these brands are selling are already available to us. In an age when (for some) skincare routines can cost over $200 a month, its helpful to revisit these concepts, and cultivate a grasp on how you can optimize your diet to help your skins greater cause preferably without having to rely on more subscription boxes.

To that end, we sourced a panel of 11 expert dermatologists and nutritionists and asked them a variety of questions. What foods are harmful to the skin? What foods are now seen as beneficial? Where do antioxidants fit in? Is turmeric overhyped? Find their answers below, including ruminations on gut health, sulfur and the best food to protect against sun damage.

Spoiler: it isnt M&Ms.

Skin is the bodys largest organ. When were not eating well or chronically stressed, inflamed skin is often the first telltale sign that somethings going on internally.There arent any serums, masks, creams or supplements that can take the place of a healthy diet.You can spend thousands on skincare products and supplements, but if youre eating poorly, your skin will show it. Nicole DeMasi, MS, RDN, CDCES, Founder of DeMasi Nutrition

People who are seriously concerned about optimizing their skincare routines should pay attention to diet: we are what we eat, and the skin shows it. Many dermatologic studies have shown a correlation between diet and common skin diseases such as acne and rosacea. There is also ample scientific evidence showing that our diet directly ages the skin, even leading to wrinkle. Oxidative stress can actually be linked back to certain foods it occurs when there are too many free radicals in the bodys cells, and not enough antioxidants to balance them. Dr. Kemunto Mokaya, board-certified dermatologist based in Knoxville,TN

Sugar is one of the absolute worst across the board when it comes to skin health. Kylene Bogden, RD,Love WellnessAdvisor,Dietician to the Cleveland Cavaliers

Sugar and high glycemic index foods(anything that converts into sugar quickly, likewhite bread, potatoes, processed foods) cause a spike in insulin, which leads to inflammation and a process called glycation. The sugar molecules attach themselves to the proteins in collagen and make collagenlose its elasticity, resulting in sagging skin.The spike in insulin can also cause a surge in testosterone, which can contribute to acne breakouts due to increased sebum production. Dr. Uzma Qureshi, MBChB, MRCGP, MRCS, medical director of MySkynClinic in Yorkshire

You may have noticed that when youve indulged a little more than usual in processed foods, it all shows up in your complexion. Sugar is one of the biggest culprits, and tends to have a major effect on skin: it activates inflammation by binding to collagen, which makes the skin appear stiff and more rigid. Jennifer Keirstead, RHN atMountain Trek Fitness Retreat & Health Spa

It isnt talked about enough, but common food senstivies like gluten and dairy can be very hard on the skin for certain people.(Im one of these people.) Heidi Moretti, MS, RD, The Healthy RD

The two most common things I eliminate with my male patients with skin concerns is cow dairy and trans fats (usually found in fried or processed food). In recent studies, dairy has been linked to increased acne and redness in the face. Your skin is made up of a large percentage of fatty cells, so poor quality fats such as trans fats found in fried foods are linked to poor skin health. Michael Robinson ND, CNS, LDN, Naturopathic Doctor and Licensed Nutritionist

Collagen is the main structural protein in the body. Its about 25-35% of the body. Without collagen, wed be just like a big puddle of skin. If you think about how inflammatory foods react in the body, they actually break down or hinder the use of proper collagen.So, ingesting inflammatory foods is actually doing the exact opposite of what were aiming for, when having great skin is our goal. Its about taking in foods that build collagen, not break it down. Dr. Christian Gonzalez, Naturopathic Doctor,Non-Toxic Living Expert, podcaster at Heal Thy Self

Vitamin Cisfound in both the epidermal (superficial) and dermal (deeper) layers of the skin. Its essential in collagen production. Peppers, dark leafy greens andBrusselssproutsaresome underrated sources. Dr. Qureshi

Vitamin C is needed in order for collagen synthesis to occur. To help promote collagen production, aim to consume foods rich in Vitamin C, such as citrus fruits, bell peppers, kiwi and strawberries, leafy greens, tomatoes and broccoli. Alex Turnbull, RD and Gut Council Member forJetson

For better skin, a large portion of the diet should include vegetables, fruits, whole-grains, legumes, seeds and nuts. Opt for healthier cooking methods like steaming and boiling. Foods rich in antioxidants help to neutralize free radicals, therefore preventing damage of collagen. Dr. Mokaya

People pay an arm and a leg to rub antioxidants like melatonin, glutathione, and resveratrol onto their skin, but these commercial products are often full of harsh chemicals. Meanwhile, those antioxidants are all available via food which benefits every cell in the body, not just where you rub the lotion. Glutathione is our master antioxidant and is found in greens like Brussels sprouts and asparagus, as well as almonds and walnuts. Melatonin is found richly in Cherries, orange bell peppers and Goji berries. Resveratrol is in dark-colored foods such as blueberries, red grapes and chocolate, as well as peanuts.Dr. Robinson

Anthocyanins are antioxidants in red and purple fruits and vegetables, and are helpful in reducing the inflammation and free-radical damage to the skin from UV light and everyday air pollution. Anthocyanins are commonly found in strawberries, raspberries, blueberries and blackberries, but cherries have the highest levels of all. So, say hello to summer fruit. Tsippora Shainhouse, MD, FAAD., board-certified dermatologist in Beverly Hills

Clinical research has shown that blemish-prone skin has a less-diverse skin microbiome. One simple way to increase the amount of good gut bacteria is to include probiotic-rich, fermented foods in the diet. These can include: unpasteurized sauerkraut, kimchi, miso and apple cider vinegar.Increase your high-fiber food intake, as theyre full of prebiotics. Prebiotics contain fibrous carbohydrates that nourish the good bacteria to help it to grow (broccoli, cauliflower, legumes, seeds, garlic, oats and avocado). The more varied your fiber sources, the more microbial diversity is encouraged. Keirstead

There are skin receptors on every organ, as well as inside our GI tract. When these receptors are disturbed and our good bacteria is thrown out of whack, you will see skin issues such as acne, psoriasis, dermatitis and others. Bogden

Many bowel conditions, such as inflammatory bowel disease,are associated with skin rashes. Improving the healthy bacteria can be done bytaking a probiotic supplement, which will add bacteria such asLactobacillus and Bifidobacteriumand help foster the presence of good bacteria.Fermented foods such as pickled vegetables, kefir,Jerusalemartichokesand natural yogurtwill then feed that bacteria so they can multiply. Dr. Qureshi

Depending on the health of your gut bugs and the integrity of your gastrointestinal barrier, you may notice skin issues flare with foods such as dairy or gluten. This occurs when a gut tissue enzyme called transglutaminase cross-reacts with the epidermal tissues transglutaminase. Gut tissue transglutaminase is what helps digest gluten, and the same enzyme that processes gluten also exists in the skin! That cross-reaction is what results in issues like hives, eczema and psoriasis. Bogden

Omega 3 oils help keep skin hydrated, reduce inflammation and help the skin to repair itself.It also works to create strong cell membranes.You can find itinwalnuts, seafood and fatty fish. Dr. Qureshi

Salmon, mackerel, tuna and sardines are fatty fish that contain high levels of omega-3 fatty acids, which are known to reduce inflammation in the body and skin. Two to three servings a week can also help reduce LDL cholesterol and triglyceride levels. Adding these fish to the diet will help balance the omega 3-to-omega 6 fatty ratio (the latter of which can actually trigger inflammation). Fish oil supplements also make a fine substitute. Shainhouse

Zinc, which can be found in foods like oysters, fortified cereals, chickpeas and cashews has been shown to help reduce inflammation and may be beneficial for people who suffer from acne. Erin Jensen PA-C, founder of California-basedThe Treatment Skin Boutique.

Eating sulfur-rich foods is also super important for glowing skin. Foods like broccoli, cauliflower, onions, garlic, Brussels sprouts. Dr. Gonzalez

Foods thigh in beta carotene, meanwhile, can help protect against sun damage. Think carrots, pumpkins and sweet potatoes. Specifically, flaxseed contains alpha-linolenic acid (ALA).Ground flaxseeds (a great source of omega-3 fatty acids) will also protect against sun damage and the fortify the skin, by helping to decrease molecules that contribute to inflammation. Also, olive oil, a great source of heart healthy fats, which may have an impact on protecting our skin from sun damage. Turnbull

It is absolutely essential that your body gets enough water. Staying hydrated ensures that nutrients actually reach your skin cells. Avoid sugary drinks and enjoy water or green tea, which is known to be a brilliant source of antioxidants. Jensen

Alcoholis well-known to be dehydrating due to its diuretic effect, and can also trigger rosacea(askin condition where the face can turn red)in predisposed people, because it dilates the blood vessels. Caffeine, meanwhile,can cause increased levels of cortisol(astress hormone) which triggers increased levels of insulin. In turn, this causes increased sebum production and breakouts. Cortisol also ages skin by impairs the skins barrier function; it result in excess water loss, which leads to drier skin. Dr. Qureshi

Though not specifically a food, water is essential for keeping our skin healthy.Bodies are comprised of 70% water and it plays a vital role in many functions of the body, including hydrating the skin and encouraging elasticity. If youre looking for an extra boost of hydration and collagen, try incorporating bone broth into your diet.Not only is it hydrating, its rich in collagen.Turnbull

Menopausal women may want to consider phytoestrogens; these are plant-derived estrogens that can improve collagen, hydrate the skin and calm aggravated skin. Theyre in abundance in soya beans, soy products, yams, pomegranates and flaxseeds. Dr. Qureshi

There hasnt been enough research for me to confidently comment, but it likely has anti-inflammatory properties that would help in healing throughout the body. Dr. Qureshi

Tumeric contains curcumin. Its an antioxidant that has anti-inflammatory properties and helps reduce oxidative stress in the body.While turmeric is an amazing antioxidant, over-hyping it can lead to over-emphasis on its benefits at the expense of the many other wonderful antioxidants found in other natural spices. Consider clove, cinnamon, oregano, peppermint, rosemary, sage, ginger and yellow mustard seed. Of the list above, clove, cinnamon and oregano have a higher oxygen radical absorbance capacity (ORAC score) than turmeric. Dr. Mokaya

Healthy levels of vitamin D have been demonstrated to prevent skin aging. Skin aging can be viewed at the molecular level, with the shortening of telomeres, caps of genetic material on the free ends of DNA strands. As these telomeres shorten with age, they render the DNA more and more unstable, until the cell dies. One studydemonstrated that telomeres were significantly longer in patients with the highest serum vitamin D levels, compared to those with the lowest the disparity was equivalent to five years of aging. Try toincorporate foods that are high in vitamin D into your dietand supplement with 600-800 IU of vitamin D daily (which is the recommended daily allowance, per both the National Academy of Medicine and the Skin Cancer Foundation). Shainhouse

The problem with labeling certain foods as beauty foods is that it over-emphasizes them at the expense of other healthy and beneficial foods. Those foods become a fad, and others, which have their own benefits, are then overlooked.Eating a plant-based, whole-food diet that emphasizes variety should be the revolution not just focusing on a few super foods that made it onto a list. Dr. Mokaya

Get away from the processed sugar and packaged foods, start to eat tons of dark leafy greens, adequate hydration and real food, and you will start to see a difference within a week or two. Bogden

Skin takes 120 days on average to rejuvenate. So any changes to diet need to be sustained in order to see benefit rather than be sporadic. Skincare is essential as the skin needs help as it ages to maintain youthful qualities. Dr. Qureshi

Overall, long-term consumption of fresh, fermented, minimally processed, whole foods is the key. It isnt one specific superfood that will ultimately be responsible for the health of any bodily system. And just as important to note: treating yourself to substances like sugar can be critical to the enjoyment of life, achieving a sustainable healthy lifestyle and activating your pleasure systems. Its what you do most of the time that matters. Balance is everything. Keirstead

Subscribe herefor our free daily newsletter.

Read the original post:
How to Eat Your Way to Healthier Skin - InsideHook

TOKYO, July 1, 2020 /PRNewswire/ --Hitachi, Ltd.(TSE: 6501, "Hitachi") and ThinkCyte, Inc. ("ThinkCyte") today announced that they have entered into a collaboration focused on developing an artificial intelligence (AI)-driven cell analysis and sorting system. Hitachi provides a broad range of solutions such as automated cell culture technologies to pharmaceutical companies in the value chain*1 of the regenerative medicine and cell therapy industry. Through the addition of this cell analysis and sorting system to the value chain, Hitachi continues contributing to cost reductions in the manufacturing of regenerative medicine and cell therapy products.Further, Hitachi and ThinkCyte are promoting collaboration with pharmaceutical companies and research institutes working in the field of regenerative medicine and cell therapy to expedite the development of the system toward commercialization.

The practical applications of regenerative medicine and cell therapy using cells for treatment have been expanding rapidly with the first regulatory approval of CAR-T*2 therapy for leukemia in 2017 in the United States and 2019 in Japan. The global market for regenerative medicine and cell therapy is expected to grow from US$ 5.9 billion (JPY 630 billion) in 2020 to US$ 35.4 billion (JPY 3.8 trillion) in 2025*3. In order to scale up treatment using regenerative medicine and cell therapy products, it is critical to ensure consistent selection and stable supply of high quality cells in large quantities and at a low costs.

Hitachi has been providing large-scale automated induced pluripotent stem (iPS) cell culture equipment, cell processing facilities (CPFs), manufacturing execution systems(MES), and biosafety cabinets among other products to pharmaceutical companies and research institutes, and has developed a value chain to meet a variety of customer needs in the regenerative medicine and cell therapy industry. Hitachi has also been carrying out collaborative research projects with universities, research institutes, and other companies to develop core technologies for pharmaceutical manufacturing instruments and in vitro diagnostic medical devices, prototyping for mass production, and working on manufacturing cost reduction and the development of stable and reliable instruments.

ThinkCyte has been performing research and development focused on high-throughput single cell analysis and sorting technology to precisely analyze and isolate target cells. While such single cell analysis and sorting technologies are vital to life science and medical research, it has been thought impossible to achieve high-throughput cell sorting based on high-content image information of every single cell. ThinkCyte has developed the world's first Ghost Cytometrytechnology to achieve high-throughput and high-content single cell sorting*4and has been conducting collaborative research projects with multiple pharmaceutical companies and research institutes to utilize this technology in life science and medical fields.

Hitachi and ThinkCyte have initiated a joint development of the AI-driven cell analysis and sorting system based on their respective technologies, expertise, and know-how. By combining ThinkCyte's high-throughput and high-content label-free single cell sorting technology and Hitachi's know-how and capability to producing stably operative instruments on a large scale, the two companies will together develop a novel reliable system to enable high-speed label-free cell isolation with high accuracy, which has been difficult to achieve with the existing cell sorting techniques, and to realize stable, low-cost and large-scale production of cells for regenerative medicine and cell therapy.

Hitachi and ThinkCyte will further advance partnerships with pharmaceutical companies and research institutes that have been developing and manufacturing regenerative medicines and cell therapy products in Japan and other countries where demand is expected to be significant, such as North America, in order to make this technology a platform for the production of regenerative medicines and cell therapy products. At the same time, taking advantage of the high-speed digital processing technologies cultivated through the development of information and communication technology by the Hitachi group, Hitachi will integrate this safe and highly reliable instrument in its value chain for regenerative medicine and contribute to the growth of the regenerative medicine and cell therapy industry.

Note:

*1. Cell manufacturing processes, including cultivation, selection, modification, preservation, product quality control, etc.

*2. Chimeric Antigen Receptor T cells that have been genetically engineered to produce an artificial T-cell receptor for use in immunotherapy.

*3. Division of Regenerative Medicine, Japan Agency for Medical Research and Development, The final report for market research on regenerative medicine and gene therapy (2020).

*4. S, Ota et al., Ghost Cytometry, Science, 360, 1246-1251 (2018).

About the AI-driven cell analysis and cell sorting technologyThinkCyte has developed high-throughput image-based cell sorting technology based on the Ghost Cytometry technology by integrating the principles of advanced imaging technology, machine learning, and microfluidics. By applying structured illumination to cell imaging, structural information of a single cell can be converted to one-dimensional waveforms for high-throughput data analysis. Based on the judgment of a machine-learning (AI) model developed using the waveform data, target cells are isolated in a microfluidic device with high throughput and with minimal damage to the cells.

This data analysis approach eliminates time-consuming image reconstruction processes and allows high-throughput image-based single cell sorting, enabling the discrimination of cells that were previously considered difficult to distinguish by the human eye. Conventional cell sorting methods rely on the use of labels such as cell surface markers for cell sorting; in contrast, ThinkCyte's technology can sort cells without such labels by employing this unique approach. In addition to the field of regenerative medicine and cell therapy, this technology can also revolutionize drug discovery and in vitrodiagnostics fields.

About Hitachi, Ltd.Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, is focused on its Social Innovation Business that combines information technology (IT), operational technology (OT) and products. The company's consolidated revenues for fiscal year 2019 (ended March 31, 2020) totaled 8,767.2 billion yen ($80.4 billion), and it employed approximately 301,000 people worldwide. Hitachi drives digital innovation across five sectors - Mobility, Smart Life, Industry, Energy and IT - through Lumada, Hitachi's advanced digital solutions, services, and technologies for turning data into insights to drive digital innovation. Its purpose is to deliver solutions that increase social, environmental and economic value for its customers. For more information on Hitachi, please visit the company's website at https://www.hitachi.com.

About ThinkCyte, Inc.ThinkCyte, headquartered in Tokyo, Japan, is a biotechnology company, which developsinnovative life science research, diagnostics,and treatmentsusingintegrated multidisciplinary technologies, founded in 2016. The company focuses on the research and development of drug discovery, cell therapy, and diagnostic platforms using its proprietary image-based high-throughput cell sorting technology In June 2019, the company was selected for J-Startup by the Ministry of Economy, Trade and Industry of Japan. For more information on ThinkCyte, please visit the company's website at https://thinkcyte.com.

ContactsHitachi, Ltd.Analytical Systems Division, Healthcare Division, Smart Life Business Management Divisionhttps://www8.hitachi.co.jp/inquiry/healthcare/en/general/form.jsp

ThinkCyte, Inc.https://thinkcyte.com/contact

View original content to download multimedia:http://www.prnewswire.com/news-releases/hitachi-and-thinkcyte-announce-collaboration-to-develop-an-ai-driven-cell-analysis-and-sorting-system-301086729.html

SOURCE ThinkCyte, Inc.

Read more from the original source:
Hitachi and ThinkCyte announce collaboration to develop an AI-driven cell analysis and sorting system - BioSpace

Scope of the Report

The report titled Global Regenerative Medicine Market: Size & Forecast with Impact Analysis of COVID-19 (2020-2024), provides an in-depth analysis of the global regenerative medicine market with description of market sizing and growth. The analysis includes market by value, by product, by material and by region. Furthermore, the report also provides detailed product analysis, material analysis and regional analysis.

Access the PDF sample of the report @https://www.orbisresearch.com/contacts/request-sample/4707408

Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and would be driving the growth of the industry. Growth of the overall global regenerative medicine market has also been forecasted for the years 2020-2024, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

Some of the major players operating in the global regenerative medicine market are Novartis AG, Medtronic Plc, Bristol Myers Squibb (Celgene Corporation) and Smith+Nephew (Osiris Therapeutics, Inc.), whose company profiling has been done in the report. Furthermore, in this segment of the report, business overview, financial overview and business strategies of the respective companies are also provided.

Region Coverage

North AmericaEuropeAsia PacificROW

Company Coverage

Novartis AGMedtronic PlcBristol Myers Squibb (Celgene Corporation)Smith+Nephew (Osiris Therapeutics, Inc.)

Executive Summary

Regenerative medicines emphasis on regeneration or replacement of tissues, cells or organs of human body to cure the problem caused by disease or injury. The treatment fortify human cells to heal up or transplant stem cells into the body to regenerate lost tissues or organs or to recover impaired functionality. There are three types of stem cells that can be used in regenerative medicine: somatic stem cells, embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells).

The regenerative medicine also has the capability to treat chronic diseases and conditions, including Alzheimers, diabetes, Parkinsons, heart disease, osteoporosis, renal failure, spinal cord injuries, etc. Regenerative medicines can be bifurcated into different product type i.e., cell therapy, tissue engineering, gene therapy and small molecules and biologics. In addition, on the basis of material regenerative medicine can be segmented into biologically derived material, synthetic material, genetically engineered materials and pharmaceuticals.

The global regenerative medicine market has surged at a progressive rate over the years and the market is further anticipated to augment during the forecasted years 2020 to 2024. The market would propel owing to numerous growth drivers like growth in geriatric population, rising global healthcare expenditure, increasing diabetic population, escalating number of cancer patients, rising prevalence of cardiovascular disease and surging obese population.

Though, the market faces some challenges which are hindering the growth of the market. Some of the major challenges faced by the industry are: legal obligation and high cost of treatment. Whereas, the market growth would be further supported by various market trends like three dimensional bioprinting , artificial intelligence to advance regenerative medicine, etc.

Browse the full report @https://www.orbisresearch.com/reports/index/global-regenerative-medicine-market-size-and-forecast-with-impact-analysis-of-covid-19-2020-2024

Table of Contents

1. Executive Summary

2. Introduction

2.1 Regenerative Medicine: An Overview2.2 Regeneration in Humans: An Overview2.3 Expansion in Peripheral Industries of Regenerative Medicine2.4 Approval System for Regenerative Medicine Products2.5 Regenerative Medicine Segmentation

3. Global Market Analysis

3.1 Global Regenerative Medicine Market: An Analysis

3.1.1 Global Regenerative Medicine Market by Value3.1.2 Global Regenerative Medicine Market by Products (Cell Therapy, Tissue Engineering, Gene Therapy and Small Molecules and Biologics)3.1.3 Global Regenerative Medicine Market by Material (Biologically Derived Material, Synthetic Material, Genetically Engineered Materials and Pharmaceuticals)3.1.4 Global Regenerative Medicine Market by Region (North America, Europe, Asia Pacific and ROW)

3.2 Global Regenerative Medicine Market: Product Analysis

3.2.1 Global Cell Therapy Regenerative Medicine Market by Value3.2.2 Global Tissue Engineering Regenerative Medicine Market by Value3.2.3 Global Gene Therapy Regenerative Medicine Market by Value3.2.4 Global Small Molecules and Biologics Regenerative Medicine Market by Value

3.3 Global Regenerative Medicine Market: Material Analysis

3.3.1 Global Biologically Derived Material Market by Value3.3.2 Global Synthetic Material Market by Value3.3.3 Global Genetically Engineered Materials Market by Value3.3.4 Global Regenerative Medicine Pharmaceuticals Market by Value

4. Regional Market Analysis

4.1 North America Regenerative Medicine Market: An Analysis4.1.1 North America Regenerative Medicine Market by Value

4.2 Europe Regenerative Medicine Market: An Analysis4.2.1 Europe Regenerative Medicine Market by Value

4.3 Asia Pacific Regenerative Medicine Market: An Analysis4.3.1 Asia Pacific Regenerative Medicine Market by Value

4.4 ROW Regenerative Medicine Market: An Analysis4.4.1 ROW Regenerative Medicine Market by Value

5. COVID-19

5.1 Impact of Covid-195.2 Response of Industry to Covid-195.3 Variation in Organic Traffic5.4 Regional Impact of COVID-19

6. Market Dynamics

6.1 Growth Drivers6.1.1 Growth in Geriatric Population6.1.2 Rising Global Healthcare Expenditure6.1.3 Increasing Diabetic Population6.1.4 Escalating Number of Cancer Patients6.1.5 Rising Prevalence of Cardiovascular Disease6.1.6 Surging Obese Population

6.2 Challenges6.2.1 Legal Obligation6.2.2 High Cost of Treatment

6.3 Market Trends6.3.1 3D Bio-Printing6.3.2 Artificial Intelligence to Advance Regenerative Medicine

7. Competitive Landscape

7.1 Global Regenerative Medicine Market Players: A Financial Comparison7.2 Global Regenerative Medicine Market Players by Research & Development Expenditure

8. Company Profiles

8.1 Bristol Myers Squibb (Celgene Corporation)8.1.1 Business Overview8.1.2 Financial Overview8.1.3 Business Strategy

8.2 Medtronic Plc8.2.1 Business Overview8.2.2 Financial Overview8.2.3 Business Strategy

8.3 Smith+Nephew (Osiris Therapeutics, Inc.)8.3.1 Business Overview8.3.2 Financial Overview8.3.3 Business Strategy

8.4 Novartis AG8.4.1 Business Overview8.4.2 Financial Overview8.4.3 Business Strategy

Direct purchase the report @https://www.orbisresearch.com/contact/purchase-single-user/4707408

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:

Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: +1 (972)-362-8199; +91 895 659 5155

See the rest here:
2020-2024 Global Regenerative Medicine Market with Impact Analysis of COVID-19, Production, Revenue, Demand & Applications - Apsters News

SAN FRANCISCO, June 29, 2020 /PRNewswire/ --Entitled "Randomized, Double Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptin in Combination with Filgrastim in Early Recovery Post-Myocardial Infarction: rationale, design and first interim analysis", the presentation provides an initial insight into patient outcomes of the trial that is currently ongoing in multiple centers. Patients included in this trial experienced a severe form of Myocardial Infarction known as STEMI. Soon after the initial intervention to re-establish adequate blood flow to the coronary arteries, patients begin a two-week treatment with Recardio's dutogliptin, a small molecule that enables sustained homing of mobilised stem cells to the site of cardiac injury. By releasing paracrine factors, stem cells have been shown to have significant repair and regenerative effects that improve healing and recovery of cardiac function after the infarction.

More information about the clinical program is available by visiting the "clinicaltrials.gov" website at the following link:https://clinicaltrials.gov/ct2/show/NCT03486080

About Recardio

Recardio Inc. is a clinical-stage life science company focusing ontherapies for cardiovascular, oncology and infectious diseases. The company is located in San Francisco, California, and hasoperations in the USA and Europe.The company's lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating various chemokines like SDF-1, a protein that is critical for cardiac regeneration. In addition to its current Phase 2 cardiovascular clinical program, Recardio will fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases including acute myocardial infarction and chronic heart failure, with the potential of improving heart function, quality of life and survival.

For more information, visit:http://www.recardio.eu/or contact[emailprotected]

SOURCE Recardio

Home

Read this article:
Interim Analysis of Recardio's Phase II Clinical Trial to Be Presented at the 2020 Congress of the European Society of Cardiology - PRNewswire

Pune, Maharashtra, India, June 29 2020 (Wiredrelease) Data Bridge Market Research A New Business Intelligence Report released by Data Bridge Market Research with title Global Exosome Therapeutic Market size, share, growth, Industry Trends and Forecast 2027 has abilities to raise as the most significant market worldwide as it has remained playing a remarkable role in establishing progressive impacts on the universal economy. The Global Exosome Therapeutic Market Report offers energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research is derived through primary and secondary statistics sources and it comprises both qualitative and quantitative detailing. This report has been crafted as the result of persistent efforts lead by knowledgeable forecasters, innovative analysts and brilliant researchers who indulge in detailed and diligent research on different markets, trends and emerging opportunities in the successive direction for the business needs.

Download Exclusive Sample Report (350 Pages PDF with All Related Graphs & Charts) For Free@:https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market

DBMR Analyses that the Exosome Therapeutic Market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

Increased number of exosome therapeutics as compared to the past few years will accelerate market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

KNOW YOUR OPTIONS IN THE FIGHT AGAINST COVID-19

The COVID-19 Pandemic has created bottlenecks across industry pipelines, sales funnels, and supply chain activities. This has created unprecedented budget pressure on company spending for industry leaders. This has increased requirement for opportunity analysis, price trend knowledge and competitive outcomes. Use the DBMR team to create new sales channels and capture new markets previously unknown. DBMR helps its clients to grow in these uncertain markets.

To Understand How COVID-19 Impact is covered in This Report. Get Sample Copy of the Report@https://www.databridgemarketresearch.com/request-covid-19/global-exosome-therapeutic-market

The Global Exosome Therapeutic market 2020 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Global Exosome Therapeutic Market Share analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. For each manufacturer covered, this report analyzes their Exosome Therapeutic manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

Major Players in Global Exosome Therapeutic Market Include

evox THERAPEUTICSEXOCOBIOExopharmAEGLE TherapeuticsUnited Therapeutics CorporationCodiak BioSciencesJazz Pharmaceuticals, Inc.Boehringer Ingelheim International GmbHReNeuron Group plcCapricor TherapeuticsAvalon Globocare Corp.CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC.Stem Cells Group..

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart)@https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market

New Exosome Therapeutic Market Developments in 2019

In January 2019, Codiak BioSciences has collaborated with Jazz Pharmaceuticals, Inc. to develop and commercialize exosome therapeutics to treat cancer. The collaboration will help the company to address issues which have been often implicated in solid tumors and hematological malignancies.

In October 2018, Avalon GloboCare Corp. has collaborated with Weill Cornell Medicine to form standards in cGMP-grade for human endothelial cells sourced exosome which is significant for organ regeneration and vascular health and isolation and identification of exosomes sourced from tissue for liquid biopsy and clinical use. The collaboration will help the company to lead market as exosome isolation system as will be first in the world for standardization processing of cGMP-grade exosomes for clinical studies.

In July 2018, Capricor Therapeutics has formed collaboration with the U.S. Army Institute of Surgical Research (USAISR) to discover potential for CAP-2003 (exosomes) in order to address trauma-related conditions and injuries. The collaboration will help to test CAP-2003 as a tool for preservation of life.

This research is categorized differently considering the various aspects of this market. It also evaluates the current situation and the future of the market by using the forecast horizon. The forecast is analyzed based on the volume and revenue of this market. The tools used for analyzing the Global Exosome Therapeutic Market research report include SWOT analysis.

The Global Exosome Therapeutic segments and Market Data Break Down are illuminated below:

By Type (Natural Exosomes, Hybrid Exosomes

By Source (Dendritic Cells, Mesenchymal Stem Cells, Blood, Milk, Body Fluids, Saliva, Urine Others)

By Therapy (Immunotherapy, Gene Therapy, Chemotherapy)

By Transporting Capacity (Bio Macromolecules, Small Molecules

By Application (Oncology, Neurology, Metabolic Disorders, Cardiac Disorders, Blood Disorders, Inflammatory Disorders, Gynecology Disorders, Organ Transplantation, Others)

By Route of administration (Oral, Parenteral)

By End User (Hospitals, Diagnostic Centers, Research & Academic Institutes)

If you have any Enquiry please click here @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market

The Global Exosome Therapeutic Market in terms of investment potential in various segments of the market and illustrate the feasibility of explaining the feasibility of a new project to be successful in the near future. The core segmentation of the global market is based on product types, SMEs and large corporations. The report also collects data for each major player in the market based on current company profiles, gross margins, sales prices, sales revenue, sales volume, photos, product specifications and up-to-date contact information.

What are the strengths and weaknesses of the key vendors?

Definitively, this report will give you an unmistakable perspective on every single reality of the market without a need to allude to some other research report or an information source. Our report will give all of you the realities about the past, present, and eventual fate of the concerned Market.

Scope of the Exosome Therapeutic Market

The global exosome therapeutic market is segmented on the basis of countries into U.S., Mexico, Turkey, Hong Kong, Australia, South Korea, Argentina, Colombia, Peru, Chile, Ecuador, Venezuela, Panama, Dominican Republic, El Salvador, Paraguay, Costa Rica, Puerto Rico, Nicaragua and Uruguay.

All country based analysis of the exosome therapeutic market is further analyzed based on maximum granularity into further segmentation. On the basis of type, the market is segmented into natural exosomes and hybrid exosomes. Based on source, the market is segmented into dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, urine and others. On the basis of therapy, the market is segmented into immunotherapy, gene therapy and chemotherapy. On the basis of transporting capacity, the market is segmented into bio macromolecules and small molecules. On the basis of application, the market is segmented into oncology, neurology, metabolic disorders, cardiac disorders, blood disorders, inflammatory disorders, gynecology disorders, organ transplantation and others. On the basis of route of administration, the market is segmented into pa oral and parenteral. On the basis of end user, the market is segmented into hospitals, diagnostic centers and research & academic institutes and others.

Some Points from Table of Content:

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Regulatory Scenario by Region/Country1.4 Market Investment Scenario Strategic1.5 Market Analysis by Type1.5.1 Global Exosome Therapeutic Market Share by Type (2020-2027)1.5.2 Type 11.5.3 Type 21.5.4 Other1.6 Market by Application1.6.1 Global Exosome Therapeutic Market Share by Application (2020-2027)1.6.2 Application 11.6.3 Application 21.6.4 Other1.7 Exosome Therapeutic Industry Development Trends under COVID-19 Outbreak1.7.1 Region COVID-19 Status Overview1.7.2 Influence of COVID-19 Outbreak on Exosome Therapeutic Industry Development

Global Market Growth Trends2.1 Industry Trends2.1.1 SWOT Analysis2.1.2 Porters Five Forces Analysis2.2 Potential Market and Growth Potential Analysis2.3 Industry News and Policies by Regions2.3.1 Industry News2.3.2 Industry Policies3 Value Chain of Exosome Therapeutic Market3.1 Value Chain Status3.2 Exosome Therapeutic Manufacturing Cost Structure Analysis3.2.1 Production Process Analysis3.2.2 Manufacturing Cost Structure of Exosome Therapeutic3.2.3 Labor Cost of Exosome Therapeutic3.3 Sales and Marketing Model Analysis3.4 Downstream Major Customer Analysis (by Region)

4 Players Profiles4.1 Player 14.1.1 Player 1 Basic Information4.1.2 Exosome Therapeutic Product Profiles, Application and Specification4.1.3 Player 1 Exosome Therapeutic Market Performance (2015-2020)4.1.4 Player 1 Business Overview4.2 Player 24.2.1 Player 2 Basic Information4.2.2 Exosome Therapeutic Product Profiles, Application and Specification4.2.3 Player 2 Exosome Therapeutic Market Performance (2015-2020)4.2.4 Player 2 Business Overview4.3 Player 34.3.1 Player 3 Basic Information4.3.2 Exosome Therapeutic Product Profiles, Application and Specification4.3.3 Player 3 Exosome Therapeutic Market Performance (2015-2020)4.3.4 Player 3 Business Overview4.4 Player 44.4.1 Player 4 Basic Information4.4.2 Exosome Therapeutic Product Profiles, Application and Specification4.4.3 Player 4 Exosome Therapeutic Market Performance (2015-2020)4.4.4 Player 4 Business Overview4.5 Player 54.5.1 Player 5 Basic Information4.5.2 Exosome Therapeutic Product Profiles, Application and Specification4.5.3 Player 5 Exosome Therapeutic Market Performance (2015-2020)

4.5.4 Player 5 Business Overview5 Global Exosome Therapeutic Market Analysis by Regions5.1 Global Exosome Therapeutic Sales, Revenue and Market Share by Regions5.1.1 Global Exosome Therapeutic Sales by Regions (2015-2020)5.1.2 Global Exosome Therapeutic Revenue by Regions (2015-2020)5.2 North America Exosome Therapeutic Sales and Growth Rate (2015-2020)5.3 Europe Exosome Therapeutic Sales and Growth Rate (2015-2020)5.4 Asia-Pacific Exosome Therapeutic Sales and Growth Rate (2015-2020)5.5 Middle East and Africa Exosome Therapeutic Sales and Growth Rate (2015-2020)5.6 South America Exosome Therapeutic Sales and Growth Rate (2015-2020)

11 Global Exosome Therapeutic Market Segment byTypes12 Global Exosome Therapeutic Market Segment by Applications13 Exosome Therapeutic Market Forecast by Regions (2020-2027)ContinuedComplete Report Is Available| Get Free TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market

Thanks for reading this article, we can also provide customized report as per companys specific needs. You can also get separate chapter wise or region wise report versions including North America, Europe or Asia.

Our Other Reports:-

Digital Forensics Market Size, Global Growth Analysis 2020, Technology Trends, Latest Innovation by Cellebrite, MSBA, OpenText Corp, Oxygen Forensics, Digital Forensics

Pharmacogenomics Market Size, Industry Analysis by Share, Dynamics, Global Trends, Future Growth Demand, Top Players: Abbott, AstraZeneca, Bayer AG, F. Hoffmann-La Roche Ltd: Says DBMR

Robotic Prosthetics Market 2020 Size, Industry Demand, Growth, Trends, Latest Tech & Innovation by Human Technology, HDT Global, SynTouch, Ottobock, Endolite

Care Services Market to Grow with 16.1% CAGR by 2027|Global Industry Size, Share, Growth & Latest Technology by EXL, Casenet, LLC, Medecision, IBM, Cognizant, Cerner

Generic Drug Market Size, Share, Growth, Industry Demand, Revenue, Competitive Outlook:-Pfizer, Teva Pharmaceutical, Lupin, Dr. Reddys Laboratories

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Contact:Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Corporatesales@databridgemarketresearch.com

This content has been published by Data Bridge Market Research company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at contact@wiredrelease.com.

Read more here:
Exosome Therapeutic Market Size, 2020-New Technological Change Helping Market, Application, Driver, - PharmiWeb.com

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Mercks anti-PD-1 therapy, as monotherapy for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer. The approval is based on results from the Phase 3 KEYNOTE-177 trial, in which KEYTRUDA significantly reduced the risk of disease progression or death by 40% (HR=0.60 [95% CI, 0.45-0.80; p=0.0004]) compared with chemotherapy, the current standard of care. In the study, treatment with KEYTRUDA also more than doubled median progression-free survival (PFS) compared with chemotherapy (16.5 months [95% CI, 5.4-32.4] versus 8.2 months [95% CI, 6.1-10.2]).

Todays approval has the potential to change the treatment paradigm for the first-line treatment of patients with MSI-H colorectal cancer, based on the important findings from KEYNOTE-177 that showed KEYTRUDA monotherapy demonstrated superior progression-free survival compared to standard of care chemotherapy, said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. Our commitment to pursuing biomarker research continues to help us bring new treatments to patients, particularly for those who have few available options.

Immune-mediated adverse reactions, which may be severe or fatal, can occur with KEYTRUDA, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis and renal dysfunction, severe skin reactions, solid organ transplant rejection, and complications of allogeneic hematopoietic stem cell transplantation (HSCT). Based on the severity of the adverse reaction, KEYTRUDA should be withheld or discontinued and corticosteroids administered if appropriate. KEYTRUDA can also cause severe or life-threatening infusion-related reactions. Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman. For more information, see Selected Important Safety Information below.

This approval was granted less than one month following the submission of a new supplemental Biologics License Application (sBLA), which was reviewed under the FDAs Real-Time Oncology Review (RTOR) pilot program. This review also was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence that provides a framework for concurrent submission and review of oncology drugs among its international partners. For this application, a modified Project Orbis was undertaken, and the FDA is collaborating with the Australian Therapeutic Goods Administration, Health Canada and Swissmedic on their ongoing review of the application.

Patients with unresectable or metastatic MSI-H colorectal cancer have historically faced poor outcomes, and until today, chemotherapy-containing regimens were the only FDA-approved first-line treatment options, said Luis A. Diaz, M.D., head of the division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center. In patients who were treated with KEYTRUDA and responded (n=67) in the KEYNOTE-177 trial, 43% of patients experienced a duration of response lasting two years or longer. This approval helps address the unmet need to provide a new monotherapy treatment option for patients.

Data Supporting the Approval

The approval was based on data from KEYNOTE-177 (NCT02563002), a multi-center, randomized, open-label, active-controlled trial that enrolled 307 patients with previously untreated unresectable or metastatic MSI-H or dMMR colorectal cancer. Microsatellite instability (MSI) or mismatch repair (MMR) tumor status was determined locally using polymerase chain reaction or immunohistochemistry, respectively. Patients with autoimmune disease or a medical condition that required immunosuppression were ineligible.

Patients were randomized 1:1 to receive KEYTRUDA 200 mg intravenously every three weeks or investigators choice of the following chemotherapy regimens given intravenously every two weeks:

Treatment with KEYTRUDA or chemotherapy continued until Response Evaluation Criteria in Solid Tumors (RECIST) v1.1-defined progression of disease as determined by the investigator or unacceptable toxicity. Patients treated with KEYTRUDA without disease progression could be treated for up to 24 months. Assessment of tumor status was performed every nine weeks. Patients randomized to chemotherapy were offered KEYTRUDA at the time of disease progression. The main efficacy outcome measure was progression-free survival (PFS) as assessed by blinded independent central review (BICR) according to RECIST v1.1, modified to follow a maximum of 10 target lesions and a maximum of five target lesions per organ, and overall survival (OS). Additional efficacy outcome measures were objective response rate (ORR) and duration of response (DOR).

Patients were enrolled and randomized to KEYTRUDA (n=153) or chemotherapy (n=154). The baseline characteristics of these 307 patients were: median age of 63 years (range, 24 to 93), 47% age 65 or older; 50% male; 75% White and 16% Asian; 52% had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, and 48% had an ECOG PS of 1; and 27% received prior adjuvant or neoadjuvant chemotherapy. Among the 154 patients randomized to receive chemotherapy, 143 received chemotherapy per the protocol. Of these 143 patients, 56% received mFOLFOX6, 44% received FOLFIRI, 70% received bevacizumab plus mFOLFOX6 or FOLFIRI, and 11% received cetuximab plus mFOLFOX6 or FOLFIRI. The median follow-up time was 27.6 months (range, 0.2 to 48.3 months).

In this study, KEYTRUDA monotherapy significantly reduced the risk of disease progression or death by 40% (HR=0.60 [95% CI, 0.45-0.80; p=0.0004]) and showed a median PFS of 16.5 months (95% CI, 5.4-32.4) compared with 8.2 months (95% CI, 6.1-10.2) for patients treated with chemotherapy. For PFS, in the KEYTRUDA arm, there were 82 patients (54%) with an event versus 113 patients (73%) in the chemotherapy arm. At the time of the PFS analysis, the OS data were not mature (66% of the required number of events for the OS final analysis). For patients treated with KEYTRUDA, the ORR was 44% (95% CI, 35.8-52.0), with a complete response rate of 11% and a partial response rate of 33%, and for patients treated with chemotherapy, the ORR was 33% (95% CI, 25.8-41.1), with a complete response rate of 4% and a partial response rate of 29%. Median DOR was not reached (range, 2.3+ to 41.4+) with KEYTRUDA versus 10.6 months (range, 2.8 to 37.5+) with chemotherapy. Based on 67 patients with a response in the KEYTRUDA arm and 51 patients with a response in the chemotherapy arm, 75% in the KEYTRUDA arm had a duration of response greater than or equal to 12 months versus 37% in the chemotherapy arm, and 43% in the KEYTRUDA arm had a duration of response greater than or equal to 24 months versus 18% in the chemotherapy arm.

Among the 153 patients with MSI-H or dMMR colorectal cancer treated with KEYTRUDA, the median duration of exposure to KEYTRUDA was 11.1 months (range, 1 day to 30.6 months). Adverse reactions occurring in patients with MSI-H or dMMR colorectal cancer were similar to those occurring in 2,799 patients with melanoma or non-small cell lung cancer treated with KEYTRUDA as a single agent.

About KEYTRUDA (pembrolizumab) Injection, 100 mg

KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of the bodys immune system to help detect and fight tumor cells. KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.

Merck has the industrys largest immuno-oncology clinical research program. There are currently more than 1,200 trials studying KEYTRUDA across a wide variety of cancers and treatment settings. The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patient's likelihood of benefitting from treatment with KEYTRUDA, including exploring several different biomarkers.

Selected KEYTRUDA (pembrolizumab) Indications

Melanoma

KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma.

KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.

Non-Small Cell Lung Cancer

KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.

KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.

KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with NSCLC expressing PD-L1 [tumor proportion score (TPS) 1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic.

KEYTRUDA, as a single agent, is indicated for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS 1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.

Small Cell Lung Cancer

KEYTRUDA is indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least 1 other prior line of therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Head and Neck Squamous Cell Cancer

KEYTRUDA, in combination with platinum and fluorouracil (FU), is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC).

KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [combined positive score (CPS) 1] as determined by an FDA-approved test.

KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy.

Classical Hodgkin Lymphoma

KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or who have relapsed after 3 or more prior lines of therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Primary Mediastinal Large B-Cell Lymphoma

KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy.

Urothelial Carcinoma

KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 [combined positive score (CPS) 10], as determined by an FDA-approved test, or in patients who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

KEYTRUDA is indicated for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

Microsatellite Instability-High (MSI-H) Cancer

KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)

This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The safety and effectiveness of KEYTRUDA in pediatric patients with MSI-H central nervous system cancers have not been established.

Colorectal Cancer

KEYTRUDA is indicated for the first-line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC).

Gastric Cancer

KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS 1) as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Esophageal Cancer

KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (CPS 10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.

Cervical Cancer

KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS 1) as determined by an FDA-approved test. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Hepatocellular Carcinoma

KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Merkel Cell Carcinoma

KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC). This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Renal Cell Carcinoma

KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

Tumor Mutational Burden-High (TMB-H)

KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established.

Cutaneous Squamous Cell Carcinoma

KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.

Selected Important Safety Information for KEYTRUDA

Immune-Mediated Pneumonitis

KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases. Pneumonitis occurred in 3.4% (94/2799) of patients with various cancers receiving KEYTRUDA, including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%). Pneumonitis occurred in 8.2% (65/790) of NSCLC patients receiving KEYTRUDA as a single agent, including Grades 3-4 in 3.2% of patients, and occurred more frequently in patients with a history of prior thoracic radiation (17%) compared to those without (7.7%). Pneumonitis occurred in 6% (18/300) of HNSCC patients receiving KEYTRUDA as a single agent, including Grades 3-5 in 1.6% of patients, and occurred in 5.4% (15/276) of patients receiving KEYTRUDA in combination with platinum and FU as first-line therapy for advanced disease, including Grades 3-5 in 1.5% of patients.

Monitor patients for signs and symptoms of pneumonitis. Evaluate suspected pneumonitis with radiographic imaging. Administer corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 or recurrent Grade 2 pneumonitis.

Immune-Mediated Colitis

KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 1.7% (48/2799) of patients receiving KEYTRUDA, including Grade 2 (0.4%), 3 (1.1%), and 4 (<0.1%). Monitor patients for signs and symptoms of colitis. Administer corticosteroids for Grade 2 or greater colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for Grade 4 colitis.

Immune-Mediated Hepatitis (KEYTRUDA) and Hepatotoxicity (KEYTRUDA in Combination With Axitinib)

Immune-Mediated Hepatitis

KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 0.7% (19/2799) of patients receiving KEYTRUDA, including Grade 2 (0.1%), 3 (0.4%), and 4 (<0.1%). Monitor patients for changes in liver function. Administer corticosteroids for Grade 2 or greater hepatitis and, based on severity of liver enzyme elevations, withhold or discontinue KEYTRUDA.

Hepatotoxicity in Combination With Axitinib

KEYTRUDA in combination with axitinib can cause hepatic toxicity with higher than expected frequencies of Grades 3 and 4 ALT and AST elevations compared to KEYTRUDA alone. With the combination of KEYTRUDA and axitinib, Grades 3 and 4 increased ALT (20%) and increased AST (13%) were seen. Monitor liver enzymes before initiation of and periodically throughout treatment. Consider more frequent monitoring of liver enzymes as compared to when the drugs are administered as single agents. For elevated liver enzymes, interrupt KEYTRUDA and axitinib, and consider administering corticosteroids as needed.

Immune-Mediated Endocrinopathies

KEYTRUDA can cause adrenal insufficiency (primary and secondary), hypophysitis, thyroid disorders, and type 1 diabetes mellitus. Adrenal insufficiency occurred in 0.8% (22/2799) of patients, including Grade 2 (0.3%), 3 (0.3%), and 4 (<0.1%). Hypophysitis occurred in 0.6% (17/2799) of patients, including Grade 2 (0.2%), 3 (0.3%), and 4 (<0.1%). Hypothyroidism occurred in 8.5% (237/2799) of patients, including Grade 2 (6.2%) and 3 (0.1%). The incidence of new or worsening hypothyroidism was higher in 1185 patients with HNSCC (16%) receiving KEYTRUDA, as a single agent or in combination with platinum and FU, including Grade 3 (0.3%) hypothyroidism. Hyperthyroidism occurred in 3.4% (96/2799) of patients, including Grade 2 (0.8%) and 3 (0.1%), and thyroiditis occurred in 0.6% (16/2799) of patients, including Grade 2 (0.3%). Type 1 diabetes mellitus, including diabetic ketoacidosis, occurred in 0.2% (6/2799) of patients.

Monitor patients for signs and symptoms of adrenal insufficiency, hypophysitis (including hypopituitarism), thyroid function (prior to and periodically during treatment), and hyperglycemia. For adrenal insufficiency or hypophysitis, administer corticosteroids and hormone replacement as clinically indicated. Withhold KEYTRUDA for Grade 2 adrenal insufficiency or hypophysitis and withhold or discontinue KEYTRUDA for Grade 3 or Grade 4 adrenal insufficiency or hypophysitis. Administer hormone replacement for hypothyroidism and manage hyperthyroidism with thionamides and beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for Grade 3 or 4 hyperthyroidism. Administer insulin for type 1 diabetes, and withhold KEYTRUDA and administer antihyperglycemics in patients with severe hyperglycemia.

Immune-Mediated Nephritis and Renal Dysfunction

KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 0.3% (9/2799) of patients receiving KEYTRUDA, including Grade 2 (0.1%), 3 (0.1%), and 4 (<0.1%) nephritis. Nephritis occurred in 1.7% (7/405) of patients receiving KEYTRUDA in combination with pemetrexed and platinum chemotherapy. Monitor patients for changes in renal function. Administer corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for Grade 2; permanently discontinue for Grade 3 or 4 nephritis.

Immune-Mediated Skin Reactions

Immune-mediated rashes, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) (some cases with fatal outcome), exfoliative dermatitis, and bullous pemphigoid, can occur. Monitor patients for suspected severe skin reactions and based on the severity of the adverse reaction, withhold or permanently discontinue KEYTRUDA and administer corticosteroids. For signs or symptoms of SJS or TEN, withhold KEYTRUDA and refer the patient for specialized care for assessment and treatment. If SJS or TEN is confirmed, permanently discontinue KEYTRUDA.

Other Immune-Mediated Adverse Reactions

Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue in patients receiving KEYTRUDA and may also occur after discontinuation of treatment. For suspected immune-mediated adverse reactions, ensure adequate evaluation to confirm etiology or exclude other causes. Based on the severity of the adverse reaction, withhold KEYTRUDA and administer corticosteroids. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Based on limited data from clinical studies in patients whose immune-related adverse reactions could not be controlled with corticosteroid use, administration of other systemic immunosuppressants can be considered. Resume KEYTRUDA when the adverse reaction remains at Grade 1 or less following corticosteroid taper. Permanently discontinue KEYTRUDA for any Grade 3 immune-mediated adverse reaction that recurs and for any life-threatening immune-mediated adverse reaction.

The following clinically significant immune-mediated adverse reactions occurred in less than 1% (unless otherwise indicated) of 2799 patients: arthritis (1.5%), uveitis, myositis, Guillain-Barr syndrome, myasthenia gravis, vasculitis, pancreatitis, hemolytic anemia, sarcoidosis, and encephalitis. In addition, myelitis and myocarditis were reported in other clinical trials, including classical Hodgkin lymphoma, and postmarketing use.

Treatment with KEYTRUDA may increase the risk of rejection in solid organ transplant recipients. Consider the benefit of treatment vs the risk of possible organ rejection in these patients.

Infusion-Related Reactions

KEYTRUDA can cause severe or life-threatening infusion-related reactions, including hypersensitivity and anaphylaxis, which have been reported in 0.2% (6/2799) of patients. Monitor patients for signs and symptoms of infusion-related reactions. For Grade 3 or 4 reactions, stop infusion and permanently discontinue KEYTRUDA.

Complications of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Immune-mediated complications, including fatal events, occurred in patients who underwent allogeneic HSCT after treatment with KEYTRUDA. Of 23 patients with cHL who proceeded to allogeneic HSCT after KEYTRUDA, 6 (26%) developed graft-versus-host disease (GVHD) (1 fatal case) and 2 (9%) developed severe hepatic veno-occlusive disease (VOD) after reduced-intensity conditioning (1 fatal case). Cases of fatal hyperacute GVHD after allogeneic HSCT have also been reported in patients with lymphoma who received a PD-1 receptorblocking antibody before transplantation. Follow patients closely for early evidence of transplant-related complications such as hyperacute graft-versus-host disease (GVHD), Grade 3 to 4 acute GVHD, steroid-requiring febrile syndrome, hepatic veno-occlusive disease (VOD), and other immune-mediated adverse reactions.

In patients with a history of allogeneic HSCT, acute GVHD (including fatal GVHD) has been reported after treatment with KEYTRUDA. Patients who experienced GVHD after their transplant procedure may be at increased risk for GVHD after KEYTRUDA. Consider the benefit of KEYTRUDA vs the risk of GVHD in these patients.

Increased Mortality in Patients With Multiple Myeloma

In trials in patients with multiple myeloma, the addition of KEYTRUDA to a thalidomide analogue plus dexamethasone resulted in increased mortality. Treatment of these patients with a PD-1 or PD-L1 blocking antibody in this combination is not recommended outside of controlled trials.

Embryofetal Toxicity

Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman. Advise women of this potential risk. In females of reproductive potential, verify pregnancy status prior to initiating KEYTRUDA and advise them to use effective contraception during treatment and for 4 months after the last dose.

Adverse Reactions

In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9% of 555 patients with advanced melanoma; adverse reactions leading to permanent discontinuation in more than one patient were colitis (1.4%), autoimmune hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4%), and cardiac failure (0.4%). The most common adverse reactions (20%) with KEYTRUDA were fatigue (28%), diarrhea (26%), rash (24%), and nausea (21%).

In KEYNOTE-002, KEYTRUDA was permanently discontinued due to adverse reactions in 12% of 357 patients with advanced melanoma; the most common (1%) were general physical health deterioration (1%), asthenia (1%), dyspnea (1%), pneumonitis (1%), and generalized edema (1%). The most common adverse reactions were fatigue (43%), pruritus (28%), rash (24%), constipation (22%), nausea (22%), diarrhea (20%), and decreased appetite (20%).

In KEYNOTE-054, KEYTRUDA was permanently discontinued due to adverse reactions in 14% of 509 patients; the most common (1%) were pneumonitis (1.4%), colitis (1.2%), and diarrhea (1%). Serious adverse reactions occurred in 25% of patients receiving KEYTRUDA. The most common adverse reaction (20%) with KEYTRUDA was diarrhea (28%).

In KEYNOTE-189, when KEYTRUDA was administered with pemetrexed and platinum chemotherapy in metastatic nonsquamous NSCLC, KEYTRUDA was discontinued due to adverse reactions in 20% of 405 patients. The most common adverse reactions resulting in permanent discontinuation of KEYTRUDA were pneumonitis (3%) and acute kidney injury (2%). The most common adverse reactions (20%) with KEYTRUDA were nausea (56%), fatigue (56%), constipation (35%), diarrhea (31%), decreased appetite (28%), rash (25%), vomiting (24%), cough (21%), dyspnea (21%), and pyrexia (20%).

In KEYNOTE-407, when KEYTRUDA was administered with carboplatin and either paclitaxel or paclitaxel protein-bound in metastatic squamous NSCLC, KEYTRUDA was discontinued due to adverse reactions in 15% of 101 patients. The most frequent serious adverse reactions reported in at least 2% of patients were febrile neutropenia, pneumonia, and urinary tract infection. Adverse reactions observed in KEYNOTE-407 were similar to those observed in KEYNOTE-189 with the exception that increased incidences of alopecia (47% vs 36%) and peripheral neuropathy (31% vs 25%) were observed in the KEYTRUDA and chemotherapy arm compared to the placebo and chemotherapy arm in KEYNOTE-407.

In KEYNOTE-042, KEYTRUDA was discontinued due to adverse reactions in 19% of 636 patients with advanced NSCLC; the most common were pneumonitis (3%), death due to unknown cause (1.6%), and pneumonia (1.4%). The most frequent serious adverse reactions reported in at least 2% of patients were pneumonia (7%), pneumonitis (3.9%), pulmonary embolism (2.4%), and pleural effusion (2.2%). The most common adverse reaction (20%) was fatigue (25%).

In KEYNOTE-010, KEYTRUDA monotherapy was discontinued due to adverse reactions in 8% of 682 patients with metastatic NSCLC; the most common was pneumonitis (1.8%). The most common adverse reactions (20%) were decreased appetite (25%), fatigue (25%), dyspnea (23%), and nausea (20%).

Adverse reactions occurring in patients with SCLC were similar to those occurring in patients with other solid tumors who received KEYTRUDA as a single agent.

In KEYNOTE-048, KEYTRUDA monotherapy was discontinued due to adverse events in 12% of 300 patients with HNSCC; the most common adverse reactions leading to permanent discontinuation were sepsis (1.7%) and pneumonia (1.3%). The most common adverse reactions (20%) were fatigue (33%), constipation (20%), and rash (20%).

See the original post here:
FDA Approves Merck's KEYTRUDA (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer -...

New York, July 1 : A team of US scientists, led by an Indian-origin researcher revealed that SARS-CoV-2 (coronavirus), the virus behind Covid-19, can infect heart cells in a lab dish.

This suggests it may be possible for heart cells in Covid-19 patients to be directly infected by the virus.

The discovery, published today in the journal Cell Reports Medicine, was made using heart muscle cells that were produced by stem cell technology.

We not only uncovered that these stem cell-derived heart cells are susceptible to infection by a novel coronavirus, but that the virus can also quickly divide within the heart muscle cells, said study researcher Arun Sharma from the Cedars-Sinai Board of Governors Regenerative Medicine Institute in the US.

Even more significant, the infected heart cells showed changes in their ability to beat after 72 hours of infection, Sharma added.Although many COVID-19 patients experience heart problems, the reasons remain unclear. Pre-existing cardiac conditions or inflammation and oxygen deprivation resulting from the infection have all been implicated.

But there has until now been only limited evidence the SARS-CoV-2 virus directly infects the individual muscle cells of the heart.The study also demonstrated human stem cell-derived heart cells infected by SARS-CoV-2 change their gene expression profile.This offers further confirmation the cells can be actively infected by the virus and activate innate cellular defence mechanisms in an effort to help clear-out the virus.

This viral pandemic is predominately defined by respiratory symptoms, but there are also cardiac complications, including arrhythmia, heart failure and viral myocarditis, said study co-author Clive Svendsen.

While this could be the result of massive inflammation in response to the virus, our data suggest that the heart could also be directly affected by the virus in Covid-19, Svendsen added.

Researchers also found that treatment with an ACE2 antibody was able to blunt viral replication on stem cell-derived heart cells, suggesting that the ACE2 receptor could be used by SARS-CoV-2 to enter human heart muscle cells.

By blocking the ACE2 protein with an antibody, the virus is not as easily able to bind to the ACE2 protein, and thus cannot easily enter the cell, said Sharma. This not only helps us understand the mechanisms of how this virus functions, but also suggests therapeutic approaches that could be used as a potential treatment for SARS-CoV-2 infection, he explained.

The study used human induced pluripotent stem cells (iPSCs), a type of stem cell that is created in the lab from a persons blood or skin cells. IPSCs can make any cell type found in the body, each one carrying the DNA of the individual. This work illustrates the power of being able to study human tissue in a dish, the authors wrote.

Read more:
Rahul Gandhi to interact with nurses on July 1 - WeForNews

The bones of the skeletal system serve many important functions for the body, from giving your body support to allowing you to move. They also play an important role in blood cell production and fat storage.

Bone marrow is the spongy or viscous tissue that fills the inside of your bones. There are actually two types of bone marrow:

Read on to learn more about different functions of red and yellow bone marrow as well as the conditions that affect bone marrow.

Red bone marrow is involved in hematopoiesis. This is another name for blood cell production. Hematopoietic stem cells that are found in red bone marrow can develop into a variety of different blood cells, including:

Newly produced blood cells enter your bloodstream through vessels called sinusoids.

As you age, your red bone marrow is gradually replaced with yellow bone marrow. And by adulthood, red bone marrow can be found only in a handful of bones, including the:

Yellow bone marrow is involved in the storage of fats. The fats in yellow bone marrow are stored in cells called adipocytes. This fat can be used as an energy source as needed.

Yellow bone marrow also contains mesenchymal stem cells. These are cells that can develop into bone, fat, cartilage, or muscle cells.

Remember, over time, yellow bone marrow starts to replace red bone marrow. So, most bones in an adult body contain yellow bone marrow.

Bone marrow is crucial for producing blood cells. Therefore, a range of blood-related conditions involve issues with bone marrow.

Many of these conditions affect the numbers of blood cells produced in bone marrow. This causes them to share many common symptoms, including:

Heres a look at some specific conditions involving bone marrow issues.

Leukemia is a type of cancer that can affect both your bone marrow and lymphatic system.

It happens when blood cells get mutations in their DNA. This causes them to grow and divide more rapidly than healthy blood cells. Over time, these cells start to crowd out the healthy cells in your bone marrow.

Leukemia is classified as either acute or chronic, depending on how fast it progresses. Its further broken down by the type of white blood cells it involves.

Myelogenous leukemia involves red blood cells, white blood cells, and platelets. Lymphocytic leukemia involves lymphocytes, a specific type of white blood cell.

Some of the major types of leukemia include:

Theres no clear cause of leukemia, but certain things can increase your risk, including:

Aplastic anemia occurs when bone marrow doesnt produce enough new blood cells. It occurs from damage to the stem cells of bone marrow. This makes it harder from them to grow and develop into new blood cells.

This damage can be either:

Myeloproliferative disorders happen when the stem cells in bone marrow grow abnormally. This can lead to increased numbers of a specific type of blood cell.

There are several types of myeloproliferative disorders, including:

Bone marrow is found in the bones throughout your body. There are two types of bone marrow. Red bone marrow is involved in production of blood cells, while yellow marrow is important for fat storage. As you age, yellow bone marrow replaces red bone marrow.

Read more from the original source:
Function of Bone Marrow: What Is Bone Marrow, and What ...

Patients with cancer often incur bone marrow damage, resulting in the destruction of stem cells. Stem cell transplants are used to replenish lost or damaged cells that have been affected by cancer and depending on where the stem cells come from these, the procedure may be a bone marrow transplant (BMT), peripheral blood stem cell transplant, or a cord blood transplant.

Typically, in a stem cell transplant, physicians administer high doses of chemotherapy, occasionally in conjunction with radiation therapy, to kill all cancer cells. This is known as myeloablative therapy.

Here are the two main types of transplants, as outline by the American Cancer Society:

In an autologous stem cell transplant, the patient serves as their own donor. Auto means self, therefore this procedure means harvesting your own stem cells from either your blood or bone marrow, then freezing them for preservation. Following high-dose chemo and radiation therapy, the frozen cells are thawed and returned to the (self) donor. Autologous transplants are sometimes used for testicular cancer and brain tumors, but are mainly utilized to treat leukemia, lymphoma, and multiple myeloma. For the latter, autologous stem cell procedures offers patients a chance for achieving sustained remission. One advantage of autologous stem cell transplant is that youre getting your own cells back. When you getyour own stem cells back, you dont have to worry about them (called the engrafted cells or the graft) being rejected by your body, says the American Cancer Society.

Despite the benefits, as with all procedures, there are risks involved, including graft failure which occurs when the transplanted stem cells dont go into bone marrow fail to properly produce blood cells. A possible disadvantage of an autologous transplant is that cancer cells might be collected along with the stem cells and then later put back into your body, the ACS says, adding that another disadvantage of a autologous stem cell transplants is that your immune system is the same as it was before your transplant. This means the cancer cells were able to escape attack from your immune system before, and may be able to do so again.

But how exactly do physicians prevent any residual cancer cells from being transplanted with healthy cells? In a process known as purging, stem cells are treated before being infused back into the patients blood. Although purging carries its benefits, a potential downside, according to the ACS, is that normal cells may be lost during this process, which in turn could lead to unsafe levels of white blood cells as your body takes longer to produce normal blood cells. Cancer centers will also sometimes use in vivopurging, which involves not treating the stem cells, and instead administering anti-cancer drugs to patients post-transplant. The ACS notes, however, that the need to remove cancer cells from transplanted stem cells or transplant patients and the best way to do it continues to be researched.

Whereas autologous procedures infuse stem cells from your own body, allogeneic stem cell transplants use cells from a donor with a very similar tissue type (in many cases a relative, usually a sibling). In cases where the ideal donor is not a relative, physicians may opt to perform a matched unrelated donor (MUD) transplant, which as the ACS notes, are usually riskier than those with a relative who is a good match.

Allogeneic transplants comprise of the same process as autologous stem cell transplants where stem cells are harvested, frozen, and subsequently thawed and put back following high-dose chemo and/or radiation therapy. In some cases, the procedures involve the infusion of blood extracted from the placenta and umbilical cord of a newborn because the cord contains a high number of stem cells that quickly multiple. By 2017, an estimated 700,000 units (batches) of cord blood had been donated for public use. And, even more have been collected for private use. In some studies, the risk of a cancer not going away or coming back after a cord blood transplant was less than after an unrelated donor transplant, writes the ACS.

A benefit of an allogeneic transplant is that donor stem cells create their own immune cells, which may eliminate any residual cancer cells that remain after high-dose treatment, which is known as the graft-versus-cancer effect. Moreover, because the donor stem cells are free of cancer, donors can be asked to donate stem cells or white blood cells multiple times.

As with autologous stem cell procedures, this donor dependent transplant also carries risk. The transplant, or graft, might be destroyed by the patients body before reaching the bone marrow. Allogeneic stem cell transplants also augment the risk of graft-versus-host-disease, where cells from the donor attack healthy cells in the recipients body. Furthermore, despite the healthy cells being tested before transplant, allogeneic procedures still carry a certain risk of infections because, as the ACS writes, your immune system is held in check (suppressed) by medicines calledimmunosuppressivedrugs. Such infections can cause serious problems and even death.

Because theres a plethora of human leukocyte antigen (HLA) combinations, which are inherited from both parents, finding an exact donor match can often be an arduous task. The search usually starts at siblings, and theres a 25% chance of a sibling being a perfect match. In the event that a sibling does not match, the search moves onto extended family (and parents) who are less likely to match.

The ACS writes: As unlikely as it seems, its possible to find a good match with a stranger. To help with this process, the team will use transplant registries, like those listed here. Registries serve as matchmakers between patients and volunteer donors. They can search for and access millions of possible donors and hundreds of thousands of cord blood units.

Go here to read the rest:
The Two Types of Stem Cell Transplants for Cancer Treatment - DocWire News

Stem cell characterization is the study of tissue-specific differentiation. Thera are various type of stem cell such as embryonic stem cell, epithelial stem cell and others. Further, various techniques are used to characterized stem cells such as immunological techniques, used for depiction of different population of stem cells. These techniques are generally based on immunochemistry using staining technique or florescent microscopy. Besides, stem cells characterization and analysis tools are used against target chronic diseases. In 2014, the San Diego (UCSD) Health System and Sanford Stem Cell Clinical Center at the University of California announced the launch of a clinical trial, in order to assess the safety of neural stem cellbased therapy in patients with chronic spinal cord injury.

Get Free Sample Copy With Impact Analysis Of COVID-19 Of Market Report @https://www.persistencemarketresearch.com/samples/31444

The factors driving the growth of stem cell characterization and analysis tools market due to increasing chronic disorders such as cancer, a diabetes and others. In addition, increasing awareness about among people about the therapeutic potency of stem cells characterization in the management of effective diseases is anticipated to increase the demand for stem cell characterization and analysis tools. Further, there are various technologies such as flow cytometry which is used to characterize the cell surface profiling of human-bone marrow and other related purposes are expected to increase the growth of stem cell characterization and analysis tools market. In addition, increasing investment by private and public organization for research activities are likely to supplement the market growth in near future.

On the other hand, the unclear guidelines and the technical limitation for the development of the product are expected to hamper the growth of stem cell characterization and analysis tools market.

Rapid increase in corona virus all around the world is expected to hamper the growth of stem cell characterization and analysis tools market. The virus outburst has become one of the threats to the global economy and financial markets. The impact has made immense decrease in revenue generation in the field of all healthcare industry growth for the market in terms of compatibility and it has led in huge financial losses and human life which has hit very hard to the core of developing as well as emerging economies in healthcare sector. It further anticipated that such gloomy epidemiological pandemic environment is going to remain in next for at least some months, and this is going to also affect the life-science market which also include the market of stem cell characterization and analysis tools market.

Based on the Products and Service Type, stem cell characterization and analysis tools market are segmented into:

Based on the Technology, stem cell characterization and analysis tools market are segmented into:

Based on the Applications, stem cell characterization and analysis tools market are segmented into:

Based on the End User, stem cell characterization and analysis tools market are segmented into:

Based on the segmentation, human embryonic stem cell is expected to dominate the market due to their indefinite life span and higher totipotency as compared to other stem cells. Further, on the basis of technology segmentations, cell production is anticipated to increase the demand for stem cell characterization and analysis tools due to their emerging applications for stem cells in drug testing in the management of the effective diseases. Furthermore, on the basis of application segmentations, oncology is expected to show significant growth rate due to increase in the number of pipelines products for the treatment of cancers or tumors. Based on the end user, pharmaceutical and biotechnology companies are expected to dominate the market due to rising global awareness about the therapeutics research activities.

You Can Buy This PMR Healthcare Report From Here @https://www.persistencemarketresearch.com/checkout/31444

Geographically, the global stem cell characterization and analysis tools market is segmented into regions such as Latin America, Europe, North America, South Asia, East Asia Middle East & Africa and Oceania. North America is projected to emerge as prominent market in the global stem cell characterization and analysis tools market due to growing cases of target chronic diseases and increasing investments for research activities. Europe is the second leading region to dominate the market due to technological advancement and also surge in therapeutic activities, funded by government across the world. Asia-pacific is likely to witness maximum growth in near future due to increasing disposable income and with the development of infrastructure.

Some of the major key players competing in the global stem cell characterization and analysis tools market are Osiris Therapeutics, Inc., Caladrius Biosciences, Inc., U.S. Stem Cell, Inc., Astellas Pharma Inc., TEMCELL Technologies Inc., BioTime Inc., Cellular Engineering Technologies Inc., Cytori Therapeutics, Inc., and BrainStorm Cell Therapeutics Inc.

Go here to read the rest:
Impact of COVID 19 pandemic on Stem Cell Characterization and Analysis Tools Market Structure and Its Segmentation - 3rd Watch News

When you compare pictures of presidents who do not alter their hair color, they all leave office considerably grayer than when they started, which some link to the stress of the office.

Marie Antoinette syndrome is a condition in which scalp hair suddenly turns white. The name comes from the story that Marie Antoinettes hair turned white the night before she was to face the guillotine during the French Revolution.

The same thing happened to survivors of atomic bomb attacks during World War II. It has long been thought that genetics, aging and stress all contribute to developing gray hair.

New research has revealed how stress contributes to graying.

On average, humans have 100,000 hair follicles in their scalp, which produce hairs of one color or another. Hair color is determined by the types of melanin produced by cells called melanocytes. Melanocytes grow from melanocyte stem cells (MeSCs) inside the hair follicle.

With age, the number of MeSCs declines, leading to hair graying in stages from the occasional gray one, to salt and pepper, to gray and then white when all the MeSCs are gone. But how stress leads to gray hair has been a mystery.

It had been thought that stress-induced graying involved hormones such as corticosterone or autoimmune reactions. Scientists did experiments in mice and found that neither of those was the cause.

However, when they blocked the receptor for the fight-or-flight hormone, noradrenaline, they stopped hair graying in response to stress in mice. Finally, they had a clue.

The main source of noradrenaline is the adrenal glands. However, when the scientists removed the adrenal glands in mice, their hair still turned gray in response to stress. Another source of the hormone is the sympathetic nervous system (SNS), which is part of the autonomic nervous system that works to regulate many functions and parts of the body without us thinking about it.

The SNS controls the fight-or-flight response to stress to prepare the whole body for physical activity. SNS nerves and MeSCs are close together in the hair follicle, and blocking those SNS nerves prevented the hairs from turning gray in response to stress. Conversely, when the SNS nerves were over-activated, the mice went gray even without stress.

Normally, MeSCs are dormant unless hair is regrowing. In response to extreme stress, MeSCs reproduce and mature into melanocytes quickly. Large numbers of melanocytes then migrate from the follicle, leaving no MeSCs in the follicles and no melanocytes to provide the pigments that give hair its color. Once they are all gone, hair will never be its original color again.

This brings up the added question about other effects of stress, including a decline in immunity and the ability to fight off infections.

The SNS system also stimulates stem cells in the bone marrow to mature into the blood cells required to protect us from infections. Nearly every organ in the body contains stem cells, and stress could have an impact on those as well.

Medical Discovery News is hosted by professors Norbert Herzog at Quinnipiac University, and David Niesel of the University of Texas Medical Branch. Learn more at http://www.medicaldiscoverynews.com.

Read the original:
How stress contributes to the graying of hair - Galveston County Daily News

- Partnership leverages Boehringer Ingelheims oncology expertise to lead trilaciclib SCLC launch sales engagements- G1 to retain full development and commercialization rights and book revenue for trilaciclib-New Drug Application (NDA) for trilaciclib submitted in June 2020

RESEARCH TRIANGLE PARK, N.C. and RIDGEFIELD, Conn., June 30, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX) and Boehringer Ingelheim today announced that the companies have entered into a co-promotion agreement for trilaciclib in the United States and Puerto Rico. Under the terms of the three-year agreement, G1 and Boehringer Ingelheim will collaborate on the commercialization of trilaciclib for its first potential indication in small cell lung cancer (SCLC), with the Boehringer Ingelheim oncology commercial team, well-established in lung cancer, leading sales force engagement initiatives. Discovered and developed by G1, trilaciclib is a first-in-class investigational therapy designed to improve outcomes for people with cancer treated with chemotherapy.

We believe that trilaciclib has the potential to benefit patients with cancer being treated with chemotherapy across a broad range of solid tumors, said Mark Velleca, M.D., Ph.D., Chief Executive Officer of G1. Our clinical trials of trilaciclib in small cell lung cancer have demonstrated significant myelopreservation benefits, and we are excited to collaborate with Boehringer Ingelheims experienced commercial oncology team to bring this innovative therapy to patients with SCLC. In addition, this capital efficient launch structure provides us with the ability to make investments in a robust development program to assess trilaciclib in other solid tumors, including colorectal cancer and breast cancer.

Under the terms of the agreement, G1 will book revenue in the United States and Puerto Rico and retain global development and commercialization rights to trilaciclib. In the U.S. and Puerto Rico, G1 will lead marketing, market access and medical engagement initiatives; Boehringer Ingelheim will lead sales force engagements. G1 will make initial payments to Boehringer Ingelheim to cover start-up expenses and pre-approval initiatives to support a successful commercial launch. G1 will pay a promotion fee of a mid-twenties percentage of net sales in the first year of commercialization, which decreases to a low double-digit/high single-digit percentage in the second and third years of commercialization, respectively (subject to certain adjustments for sales above pre-specified levels to reward out-performance). There are no payments due by either party beyond the expiration of the three-year term of the agreement. The agreement does not extend to additional indications that G1 may pursue for trilaciclib.

Boehringer Ingelheims commitment to transform treatment expectations for the oncology community extends beyond research and drives us to explore innovative solutions for patients. We are pleased to be collaborating with G1 Therapeutics and applying our commercial strengths focused on lung cancer to support a new therapy for patients with clear synergies across customer audiences, said Kelli Moran, Senior Vice President, Specialty Care, Boehringer Ingelheim. This strategic agreement builds on Boehringer Ingelheims achievements in oncology and contributes to our long-term vision to give patients new hopeby taking cancer on.

G1 received Breakthrough Therapy Designation for trilaciclib from the U.S. Food and Drug Administration (FDA) in 2019 and submitted a New Drug Application (NDA) in June 2020. More than 25,000 people in the U.S. and Puerto Rico are diagnosed with SCLC each year. Approximately 90% of SCLC patients receive first-line chemotherapy treatment, and approximately 60% of those patients receive subsequent second-line chemotherapy treatment. Chemotherapy is an effective and important weapon against cancer. However,chemotherapy does not differentiate between healthy cells and cancer cells and kills both. One of the most common side effects of chemotherapy is myelosuppression the result of damage to stem cells in the bone marrow that produce white blood cells, red blood cells and platelets. Myelosuppression often requires the administration of rescue interventions such as growth factors and blood or platelet transfusions, and may also result in chemotherapy dose delays and reductions. Immune cell damage may decrease the ability of the immune system to fight the cancer, as well as infection. Trilaciclib has the potential to be the first proactively administered myelopreservation therapy that can make chemotherapy safer and improve the patient experience.

Additional information regarding this agreement is disclosed in a Current Report on Form 8-K filed by G1 with the U.S. Securities and Exchange Commission (available here).

About TrilaciclibTrilaciclib is a first-in-class investigational therapy designed to improve outcomes for people with cancer treated with chemotherapy. Trilaciclib has received Breakthrough Therapy Designation based on positive myelopreservation data from three randomized, double-blind, placebo-controlled clinical trials in which trilaciclib was administered prior to chemotherapy treatment in patients with small cell lung cancer (SCLC). In a randomized trial of women with metastatic triple-negative breast cancer, trilaciclib improved overall survival when administered prior to chemotherapy. In June 2020, G1 submitted a New Drug Application (NDA) for trilaciclib for myelopreservation in SCLC and began a study in neoadjuvant breast cancer as part of the I-SPY 2 TRIAL. The company expects to initiate a Phase 3 trial in colorectal cancer in the fourth quarter of 2020.

About G1 TherapeuticsG1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage programs. Trilaciclib is a first-in-class FDA-designated Breakthrough Therapy designed to improve outcomes for patients being treated with chemotherapy. Rintodestrant is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. Lerociclib is a differentiated oral CDK4/6 inhibitor designed to enable more effective combination treatment strategies.

G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit http://www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

About Boehringer Ingelheim in OncologyCancer takes. Takes away time. Takes away loved ones. At Boehringer Ingelheim Oncology, we are giving patients new hopeby taking cancer on. We are dedicated to collaborating with the oncology community on a shared journey to deliver leading science.Our primary focus is in lung and gastrointestinal cancers, with the goal of delivering breakthrough, first-in-class treatments that can help win the fight against cancer. Our commitment to innovation has resulted in pioneering treatments for lung cancer and we are advancing a unique pipeline of cancer cell directed agents, immune oncology therapies and intelligent combination approachesto help combat many cancers.

About Boehringer IngelheimMaking new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.

As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of around $21.3 billion (19 billion euros). Our significant investment of over $3.9 billion (3.5 billion euros) in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.

We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation and is part of the Boehringer Ingelheim group of companies. In addition, there are Boehringer Ingelheim Animal Health in Duluth, GA and Boehringer Ingelheim Fremont, Inc. in Fremont, CA.

Boehringer Ingelheim is committed to improving lives and strengthening our communities.Please visit http://www.boehringer-ingelheim.us/csr to learn more about Corporate Social Responsibility initiatives. For more information, please visit http://www.boehringer-ingelheim.us, or follow us on Twitter @BoehringerUS.

G1 Therapeutics Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this press release include, but are not limited to, those relating to the therapeutic potential of trilaciclib, rintodestrant and lerociclib, the timing of marketing applications in theU.S. for trilaciclib in SCLC, trilaciclibs possibility to improve patient outcomes across multiple indications, rintodestrants potential to be best-in-class oral SERD, lerociclibs differentiated safety and tolerability profile over other marketed CDK4/6 inhibitors and the impact of pandemics such as COVID-19 (coronavirus), and are based on the companys expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause the companys actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in the companys filings with theU.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein and include, but are not limited to, the companys ability to complete clinical trials for, obtain approvals for and commercialize any of its product candidates; the companys initial success in ongoing clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials; the inherent uncertainties associated with developing new products or technologies and operating as a development-stage company; and market conditions. Except as required by law, the company assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contacts:Jeff MacdonaldG1 Therapeutics, Inc.Senior Director, Investor Relations & Corporate Communications919-907-1944jmacdonald@g1therapeutics.comSusan HolzBoehringer IngelheimDirector, Public Relations203-798-4265Susan.holz@boehringer-ingelheim.com

Visit link:
G1 Therapeutics and Boehringer Ingelheim Announce Co-Promotion Agreement for Trilaciclib in Small Cell Lung Cancer in the United States and Puerto...

You have access to this full article to experience the outstanding content available to SPE members and JPT subscribers.

To ensure continued access to JPT's content, please Sign In, JOIN SPE, or Subscribe to JPT

The complete paper describes an operators experience in confirming glass fiber-reinforced epoxy (GRE) as an effective alternative to high-grade corrosion-resistant alloys (CRA) to extend tubing life in high-velocity gas wells. Laboratory testing and applications in several fields, both on and offshore, and in oil-production and water-injection wells and surface-gathering lines, demonstrate that, when used within the operating limits, GRE can extend tubing life and provide life-cycle cost savings.

The material has been intensively tested in the past to determine characteristics and capabilities. Mechanical properties, fatigue resistance, chemical compatibilities, connection properties, and abrasion trials have been proved by specific laboratory tests and field trials, demonstrating that GRE can be applied inside production tubing strings. API RP15CLT, first issued in 2007, provides guidelines for the design, manufacture, qualification, and application of composite-lined carbon-steel downhole tubing in the handling and transport of multiphase fluids, hydrocarbon gases, hydrocarbon liquids, and water.

Carbon steel guarantees the systems mechanical resistance, and the internal GRE liner ensures corrosion resistance. GRE provides outstanding corrosion resistance, even in very aggressive environments.

For oil-well applications, the system consists of a GRE resin composite liner inserted inside a low-alloy carbon steel tubing with a cement grout (Fig. 1). The grout transfers pressure directly to the steel tubing even if there is little or no bonding between liner, grout, and metal.

The end of the liner is protected from mechanical damage by a GRE end cap (flare) or a T-end flange. A polymeric corrosion barrier ring usually provides the continuity of the corrosion barrier across the coupling between two adjacent flares. The lining is lightweight, adding no more than 13% of the weight of the steel pipes and eliminating the need for additional lifting equipment.

The operator has been involved in the development of deepwater gas fields with high production rates and sour environments. On the basis of corrosion assessments performed on actual field conditions, CRA (high nickel content) material was selected as most suitable for the production tubing string. Following positive experiences with the installation of GRE, the company decided to evaluate its performance in potentially high-erosion conditions, aiming to find an alternative material to high-grade CRA for installation in high-velocity gas wells that would reduce cost and delivery time. The GRE liner was selected as a cost-effective alternative to high-alloy materials starting from 2005, when GRE was successful in reducing onshore workover costs and extending the life of carbon-steel tubing in oil producer wells with high carbon dioxide and water cut, to recent installations offshore Norway in water injection wells with highly corrosive injection fluids.

The complete paper summarizes the testing and application range of GRE in corrosive environments and, through collaboration with the Polytechnic University of Milan, high-flow, direct-impact erosion testing using a continuous flow loop and a nozzle-directed solids-impingement-testing system.

The direct-impact test confirmed that GRE shows a high resistance to erosion at high velocities and solids loadings. As a reference, similar tests were performed on nickel alloy 625 material (same sand size, jet velocity, time and 90 impact angle), and provided values very close to those obtained for the GRE composites. Results could be considered comparable to those obtained on the experimental analysis performed by the Polytechnic University of Milan.

Visual inspection of the internal surface of the GRE coating following the straight pipe flow-loop erosion revealed no sign of erosion. Similarly, the thickness of the GRE coating remained unchanged, further confirming the absence of measurable or detectable mass removal.

The GRE liner has been successfully applied in several fields, onshore and offshore, as tubing corrosion protection in oil-production wells, water-injection wells, and surface flowlines. The complete paper summarizes field applications in north Africa, northeast Africa, the Middle East, and the Barents Sea (Fig. 2). The feedback from the field cases confirmed that, when used within the operating limits, the GRE material represents a valid option for life extension and lifecycle cost savings.

Economic analyses comparing GRE liners with carbon steel and CRA for water-injection and oil-production wells in onshore and offshore conditions reveal that GRE cost is more than double that of the tubing in bare carbon steel. However, alternative CRAs, which have sometimes been considered, have proved more expensive than the one used in this paper.

Original post:
Glass-Reinforced Epoxy Effective Alternative to Alloys in Gas Wells - Journal of Petroleum Technology

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Black Cumin Seed OilMarket which would mention How the Covid-19 is Affecting the Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Key Regions and Proposal for Black Cumin Seed Oil Market Players to battle Covid-19 Impact.

The Black Cumin Seed OilMarket report is one of the most comprehensive and important data about business strategies, qualitative and quantitative analysis of Global Market. It offers detailed research and analysis of key aspects of the Black Cumin Seed Oil market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the Black Cumin Seed Oil market.

Top Leading players covered in the Black Cumin Seed Oil market report: Henry Lamotte OILS GmbH, FLAVEX Naturextrakte GmbH, Henry Lamotte Oils GmbH, Kerfoot Group, Earthoil Plantations, Life Extension, Nuverus, Omega Pharma, BioPraep and More

Get PDF Sample Report With Impact of COVID-19 on Black Cumin Seed Oil [emailprotected] https://www.marketinforeports.com/Market-Reports/Request-Sample/98604

The report offers clear guidelines for players to cement a position of strength in the global Black Cumin Seed Oil market. It prepares them to face future challenges and take advantage of lucrative opportunities by providing a broad analysis of market conditions. the global Black Cumin Seed Oil market will showcase a steadyCAGR in the forecast year 2020 to 2026.

Market Segment by Type covers:Food GradeCosmetic Grade

Market Segment by Application covers:SoapHealth FoodPersonal Care Products (Massage Oils, Skin Care Products)

Our Complimentary Sample Black Cumin Seed Oil market Report Accommodate a Brief Introduction of the research report, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology.

Inquire and Get Up to 30% DiscountBy Clicking Here!https://www.marketinforeports.com/Market-Reports/Request_discount/98604

Regions Covered in the Global Black Cumin Seed Oil Market: The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Years Considered to Estimate the Black Cumin Seed Oil Market Size:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year: 2020-2026

Highlights of the Report: Accurate market size and CAGR forecasts for the period 2019-2026 Identification and in-depth assessment of growth opportunities in key segments and regions Detailed company profiling of top players of the global Black Cumin Seed Oil market Exhaustive research on innovation and other trends of the global Black Cumin Seed Oil market Reliable industry value chain and supply chain analysis Comprehensive analysis of important growth drivers, restraints, challenges, and growth prospects

For More Information:https://www.marketinforeports.com/Market-Reports/98604/Black-Cumin-Seed-Oil-market

Customization of the Report:Market Info Reports provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Get Customization of the [emailprotected]:https://www.marketinforeports.com/Market-Reports/Request-Customization/98604/Black-Cumin-Seed-Oil-market

Contact Us:Mr. Marcus KelCall: +1 415 658 9988 (International)+91 84 839 65921 (IND)Email: [emailprotected]Website: http://www.marketinforeports.com

Continued here:
Black Cumin Seed Oil Market 2026 Expected to reach Highest CAGR including major key players Henry Lamotte OILS GmbH, FLAVEX Naturextrakte GmbH, Henry...

Analytical Research has added a new report to their increasing litany of reports titled Appetite Control and Suppressants Market Report. The new study encompasses valuable insights using a variety of graphs, tables and figures that explores opportunities, trends and drivers surrounding the Appetite Control and Suppressants industry.

HNY Research projects that the Appetite Control & Suppressants market size will grow from XXX in 2019 to XXX by 2025, at an estimated CAGR of XX. The base year considered for the study is 2019, and the market size is projected from 2020 to 2025.

Download PDF Sample of Appetite Control and Suppressants Market report @https://www.arcognizance.com/enquiry-sample/997785

By Market Players:Natural Factors, NOW Foods, Bio Sense, Hydroxycut, Life Extension, Lipozene, ASquared Nutrition, Baetea, BeLive, Better Mornings, BioGanix, BioSchwartz, BRL Sports Nutrition, Dr. Joeys, EBYSU, Health Plus Prime, Healthy Delights, iPro Organic Supplements

By ApplicationNatural, Vegetarian, Gluten-Free, Organic, Vegan

By TypeCapsules, Tablets, Powders, Caplets, Drops

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

Brief about Appetite Control and Suppressants Market Report with [emailprotected] https://www.arcognizance.com/report/2020-2025-global-and-regional-appetite-control-and-suppressants-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report

Points Covered in The Report:The points that are discussed within the report are the major market players that are involved in the market such as manufacturers, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. The historical data from 2014 to 2019 and forecast data from 2020 to 2025.The growth factors of the market is discussed in detail wherein the different end users of the market are explained in detail.Data and information by manufacturer, by region, by type, by application and etc, and custom research can be added according to specific requirements.The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Reasons to PurchaseTo gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.Assess the production processes, major issues, and solutions to mitigate the development risk.To understand the most affecting driving and restraining forces in the market and its impact in the global market.Learn about the market strategies that are being adopted by leading respective organizations.To understand the future outlook and prospects for the market.Besides the standard structure reports, we also provide custom research according to specific requirements.

Single User License Copy and other purchase [emailprotected] https://www.arcognizance.com/purchase/997785

Table of Content

Chapter One: Industry Overview

Chapter Two: Major Segmentation (Classification, Application and etc.) Analysis

Chapter Three: Production Market Analysis

Chapter Four: Sales Market Analysis

Chapter Five: Consumption Market Analysis

Chapter Six: Production, Sales and Consumption Market Comparison Analysis

Chapter Seven: Major Manufacturers Production and Sales Market Comparison Analysis

Chapter Eight: Competition Analysis by Players

Chapter Nine: Marketing Channel Analysis

Chapter Ten: New Project Investment Feasibility Analysis

Chapter Eleven: Manufacturing Cost Analysis

Chapter Twelve: Industrial Chain, Sourcing Strategy and Downstream Buyers

List of Table and Figure

Figure Product PictureTable 2014-2019 Major Types Market Sales Volume And Market ShareFigure 2014-2019 Sales Volume And Growth RateFigure 2014-2019 Sales Volume And Growth RateFigure 2014-2019 Sales Volume And Growth RateFigure 2014-2019 Sales Volume And Growth RateFigure 2014-2019 Sales Volume And Growth RateFigure 2014-2019 Sales Volume And Growth RateFigure 2014-2019 Sales Volume And Growth RateFigure 2014-2019 Sales Volume And Growth RateFigure 2014-2019 Sales Volume And Growth RateTable 2014-2019 Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross And Gross MarginFigure 2014-2019 Capacity, Production And Growth RateFigure 2014-2019 Capacity, Production And Capacity Utilization Rate continued

If you have any special requirements, please let us know and we will offer you the report as you want.

Other Trending Report:

Global Lithium ion battery Market Size study, by Type and Regional Forecasts 2020-2026 @ https://www.marketwatch.com/press-release/lithium-ion-battery-market-size-study-with-covid-19-impact-2020-share-global-industry-analysis-growth-trends-segmentation-and-forecast-to-2025-2020-06-30

Note: Our report does take into account the impact of corona virus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

About us: Analytical Research Cognizance (ARC) is a trusted hub for research reports that critically renders accurate and statistical data for your business growth. Our extensive database of examined market reports places us amongst the best industry report firms. Our professionally equipped team further strengthens ARCs potential. ARC works with the mission of creating a platform where marketers can have access to informative, latest and well researched reports. To achieve this aim our experts tactically scrutinize every report that comes under their eye.

Contact Us:Ranjeet DengaleDirector SalesAnalytical Research Cognizance+1 (646) 403-4695, +91 90967 44448[emailprotected]

Originally posted here:
Appetite Control and Suppressants Market 2020 Size, Share, Business Overview, Trends and Forecast to 2025 - Cole of Duty

Recent work has called into question the reality of the rare male mating advantage, pointing out that it could be a statistical artifact of marking flies for behavioral observation or of experimental bias in collecting males. We designed an experiment to test for rare male mating advantage that avoids these sources of bias. Large numbers of males of three Drosophila pseudoobscura karyotypes were allowed to mate with females of one karyotype in population cages. The females were then isolated before multiple mating occurred and their progeny used to diagnose the males that mated them. Populations were studied at five sets of male karyotypic frequencies. The mating success of the male homokaryotypes ST/ST and CH/CH, relative to that of the heterokaryotype ST/CH, was frequency dependent. Both ST/ST and CH/CH males displayed a statistically significant mating advantage at low frequency by comparision with their mating success in the midrange of karyotypic frequencies. Both male homokaryotypes also showed a significantly greater mating success at high homokaryotypic frequency than at intermediate frequencies, which is the same as saying that the heterokaryotype not only failed to show a rare male advantage but actually suffered a mating disadvantage at low frequency. We conclude that rare male mating advantage is not always an experimental or methodological artifact but does occur in laboratory populations of D. pseudoobscura. It may occur for some genotypes and not for others, however, and it may be only one of several forms of frequency-dependent mating behavior operating in a population.

Read more here:
A TEST FOR RARE MALE MATING ADVANTAGE WITH ... - genetics.org

NEW HAVEN, Conn.--(BUSINESS WIRE)--While infertility, or the inability to conceive after one year of trying used to be a womans problem, there is now a better understanding of the important role men play in conceiving. In at least half of all infertility cases, men are either the contributing or leading cause. To help couples better understand common fertility issues, Mary Jane Minkin, MD, OB/GYN, founder of MadameOvary.com, sheds light on male fertility factors and how men can be proactive in improving their fertility.

The well-known advice for couples trying to conceive are centered around the womans fertile window or when she should start to abstain from alcohol, says Mary Jane Minkin, MD, Clinical Professor of Obstetrics & Gynecology at Yale University. However, it takes two to tango, and couples should be aware of both female and male fertility issues to improve their odds of conceiving. As science and research continues to move forward in treating infertility, realize that there are ways to address male fertility, and that 90% of infertility cases are treatable with current medical therapies.

Dr. Minkin suggests the below tips to help men be proactive when it comes to their fertility:

The trying to conceive journey looks different for every couple, adds Minkin. Both partners should remember to be proactive about their health, modify their lifestyle accordingly, and if struggling to conceive, be supportive of one another and prioritize communication.

See original here:
Men's Health Month: Mary Jane Minkin, M.D., OB/GYN Shares 5 Proactive Fertility Tips for Men When Trying to Conceive - Business Wire

VICE does not imply that Prince William has excessive sex hormones or COVID-19. Image viaSteve Parsons / POOL / AFP (cropped)

Towards the end of May, a study published by a team of Spanish researchers and dermatologists found that out of a sample of 122 male COVID-19 patients admitted to hospitals in Madrid, 79 percent were baldabout double the standard population frequency.

Four weeks later, another paper published in the Journal of Cosmetic Dermatology found bald men were similarly overrepresented among COVID-19 hospital admissions.

Both studies were small, and neither of them definitively confirmed the correlation between male pattern hair loss and susceptibility to coronavirus. But together they launched a shockwave of articles around the world proclaiming scientists fears that follicly challenged men might be at greater risk of catching, and dying from, COVID-19.

According to Jenny Graves, Professor of Genetics and Vice Chancellor's Fellow at Melbournes La Trobe University, the science more or less checks out: there may well be a plausible biological explanation for the apparent link between baldness and vulnerability to COVID. And it's got to do with sex hormones.

In a piece published for The Conversation, Dr Graves points out that male pattern hair loss is typically linked to a family of sex hormones called androgens. Androgens are commonly referred to as male hormones for the way in which they regulate the development of male characteristics, such as the development of sexual organs, the growth of the prostate, and balding.

High levels of androgen are strongly associated with hair loss. But studies suggest that these hormones might also play an important role in mediating the entry of SARS-CoV-2 (the virus that causes COVID-19) into cellsthus increasing the risk of severe infection and death.

Hence the theory that the more male hormones present in a persons body, the easier it is for the coronavirus to get in and take hold. As Dr Graves indicates, this could be one reason why men in general appear to be at greater risk of severe infection than women.

More research is needed to firm this upand Dr Graves hastens to point out that larger samples which control for age and other conditions, for one, would go a long way towards confirming whether the link between alopecia-causing androgens and COVID-19 is as significant as it appears. If it is, though, she also suggests that it might be worth looking at anti-androgens, as well as androgen deprivation therapy (ADT), as a way to potentially treat and prevent the disease.

Anti-androgens are a class of testosterone-blocking drugs that effectively prevent androgens from carrying out their biological effects in the body. Theyre already used to treat a range of conditions, including hair loss, overly high sex drive, problematic sexual urges, and prostate cancer. The idea, essentially, is this: if the hormones that cause balding also increase COVID-19 vulnerability, maybe the medicines we have to prevent balding could be used to protect against COVID-19.

Scientists are already exploring this possibility. In a study that looked at a sample of men hospitalised with COVID-19 in Italy, researchers observed that the rate of infection was four times lower in prostate cancer patients on ADT than in untreated cancer patients.

Our data suggest that cancer patients have an increased risk of SARS-CoV-2 infections compared with non-cancer patients. However, prostate cancer patients receiving ADT appear to be partially protected from SARS-CoV-2 infections, they concluded.

Results like this give credence to the idea that similar anti-androgen regimes and therapies could be used not only as treatment, but also prevention, of COVID-19.

Perhaps a single dose given to someone who tests positive to SARS-CoV-2, or has just been exposed, would suffice to lower the chance of the virus taking hold, Dr Graves speculates. But we need research to confirm this.

Follow Gavin on Twitter or Instagram

By signing up to the VICE newsletter you agree to receive electronic communications from VICE that may sometimes include advertisements or sponsored content.

View post:
Excessive Sex Hormones Could Be Making Bald Men More Vulnerable to COVID-19 - VICE

Which guy doesn't desire an aesthetic physique? For achieving this, a lot of dedication, discipline and will power is required. Most importantly, patience and a 'never say die' attitude is essential when you are aiming for the desired body.Let's take a look at five exercises for V-Cut absas we observe Men's Health Week 2020.Mens Health Week 2020: From Cleaning Foot to Keeping Your Armpit Fresh, Here Are Five Personal Hygiene Habits Every Male Should Follow.

V-Cut abs, also known as the adonis belt, sex lines, v cuts or v abs are the muscles on the lower sides of the abdomen that form a V-shape. V-Cut abs are aesthetically pleasing. In order to achieve this v-shape on abdominal muscles, one has to do rigorous workout and mainly concentrate on their diet. Apart from performing regular core exercises, it is also necessary to focus on deadlifts, squats, overhead press along with other compound exercises. It must also be noted that genetics play an important role in achieving V-Cut abs. Some people may easily develop this physique, however, there are some who have thicker skin around their abdomen or even have uneven abs, and might find it difficult to get that v-shape. Nevertheless, following below exercises with a good diet can help you achieve a strong core and perfectly well-defined rectus abdominis muscles.Men's Health Week 2020: From Cardiovascular Diseases to Erectile Dysfunction, Common Health Conditions Males Can Develop with Age!

Five Exercises For V-Cut Abs

1. Hanging Leg Raises

It is necessary to work on burning fat around lower abdominal muscles to get those v-cut abs. Performing three to four sets of hanging leg raises of 10-12 reps perfectly can help in removing lower belly fat.

2. Reverse Crunches

This exercise works not only on lower abdominal muscles but also on the upper and middle abs. It has to be performed smoothly without putting any stress on the neck to avoid injury. Reverse crunches should be performed in four sets of fifteen reps each.

3. Mountain Climber

This exercise is also included in high-intensity interval training. If performed with pace, it shoots the heart rate and effectively helps in fat loss.

4. Leg Flutters

This exercise might look simple,but it effectively works on lower abdominal muscles. Leg flutters should be regularly included in your core training for achieving V-shape abs.

5. Seated Leg Tucks

Seated leg tucks work on obliques, middle abs, upper abs and also on the lower abs. Stability and good balance are required while performing this exercise.

In order to achieve V-Cut abs, make sure that you include fresh green vegetables in your diet regularly and eat food cooked in very less oil. Cold drinks, desserts, bakery products and refined flour should be a strict no if you are aiming for those six-pack or eight-pack abs. Even if you don't reach V-Cut shape abs, you shouldn't get disheartened as these routines will at least help in reducing your visceral fat percentage that can significantly reduce the risk of heart diseases. For better results, it is recommended to get trained under a fitness trainer and get a proper diet plan from a dietician.

(The above story first appeared on LatestLY on Jul 01, 2020 09:36 AM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).

More:
Mens Health: From Hanging Leg Raises to Reverse Crunches; Here Are 5 Exercises to Get V-Cut Abs (Watch - LatestLY

NEW YORK, July 1, 2020 /PRNewswire/ -- This report is 80% complete and can be delivered within three working days post order confirmation and will include the latest impact analysis of Covid-19 in 2020 and forecast.

Read the full report: https://www.reportlinker.com/p05916725/?utm_source=PRN

Global Autoimmune Disease Diagnostics Market By Type (Systemic, Organ-Specific), By Sex (Male, Female), By Age (0-15, 15-44, 44+), By Factors (Diet, Genetics, Environmental agents), By Diagnosis (Antinuclear Antibody Test, Autoantibody Test, Others), By Types of Treatment (Nonsteroidal Anti-Inflammatory Drugs, Immune-Suppressing Drugs, Others), By Product (Kits and assays, Reagents), By End-User (Hospital, Clinics, Others), By Region, Competition, Forecast & Opportunities, 2025

Global autoimmune disease diagnostics market size was valued at USD4 billion in 2019 and projected to grow at a formidable CAGR during the forecast period.The key factor driving the growth of autoimmune disease diagnostics market is surging investment in healthcare sector.

Additionally, growing cases of autoimmune diseases is further anticipated to bode well for the growth of autoimmune disease diagnostics market across the globe in the coming years.Moreover, increasing government support in terms of providing funds is projected to bolster the market growth through 2025.

Moreover, growing implementation of lab automation technologies in developing nations such as U.S. and Europe are further aiding the market growth. The global autoimmune disease diagnostics market is segmented based on type, sex, age, factors, diagnosis, types of treatment, product, end-user, region and company.Based on product, the market can be segmented into kits and assays, reagents and instruments.

Out of which, the kits and assays segment dominated the market in terms of largest market size until 2019 and is further anticipated to maintain its leading position during the forecast period as well.This growth can be accredited to increasing adoption of kits and assays in hospitals and clinical laboratories.

Moreover, increasing prevalence of autoimmune diseases coupled with growing requirement for fast results, is expected to boost the growth of the segment in the upcoming years. Major players operating in the autoimmune disease diagnostics market include Siemens, Abbott, Bio-Rad Laboratories, Pfizer, Johnson and Johnson, Grifols, Trinity Biotech, Thermo Fisher Scientific, Inova Diagnostics, Hycor Biomedical, Euroimmun, Protagen, Roche, Quest Diagnostics, Hemagen Diagnostics, Aesku Diagnostics, Sanofi, Sun Pharmaceutical Industries Ltd., Eli Lilly, Bayer, etc. The companies operating in autoimmune disease diagnostics market across the globe are focussing more towards the expanding their share in the market. For instance, these key players are making organic strategies such as mergers and acquisitions, among others in order to survive the highly competitive industry.

Years considered for this report:

Historical Years: 2015-2018 Base Year: 2019 Estimated Year: 2020 Forecast Period: 20212025

Objective of the Study:

To analyse and forecast the market size of global autoimmune disease diagnostics market. To classify and forecast global autoimmune disease diagnostics market based on type, sex, age, factors, diagnosis, types of treatment, product, end-user, company and regional distribution. To identify drivers and challenges for global autoimmune disease diagnostics market. To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global autoimmune disease diagnostics market. To conduct pricing analysis for global autoimmune disease diagnostics market. To identify and analyse the profile of leading players operating in global autoimmune disease diagnostics market. The analyst performed both primary as well as exhaustive secondary research for this study.Initially, the analyst sourced a list of companies across the globe.

Subsequently, the analyst conducted primary research surveys with the identified companies.While interviewing, the respondents were also enquired about their competitors.

Through this technique, the analyst could include the companies which could not be identified due to the limitations of secondary research. The analyst examined the new products, distribution channels and presence of all major players across the globe. The analyst calculated the market size of global autoimmune disease diagnostics market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. The analyst sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size.

Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by the analyst.

Key Target Audience:

Autoimmune disease diagnostics companies and other stakeholders. Government bodies such as regulating authorities and policy makers Organizations, forums and alliances related to autoimmune disease diagnostics Market research and consulting firms The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as companies and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global autoimmune disease diagnostics market has been segmented into following categories, in addition to the industry trends which have also been detailed below: Market, By Type: o Systemic o Organ-specific Market, By Sex: o Male o Female Market, By Age: o 0-15 o 15-44 o 44+ Market, By Factors: o Diet o Genetics o Environmental Agents Market, By Diagnosis: o Antinuclear Antibody Test o Autoantibody Test o CBC o Comprehensive Metabolic Panel o C-reactive Protein o Erythrocyte Sedimentation Rate o Urinalysis o Imaging Test o Biopsy Market, By Types of Treatment: o Nonsteroidal Anti-Inflammatory Drugs o Immune-Suppressing Drugs o Hormone Replacement Therapy o Physical Therapy o Blood Transfusion o Plasma Exchange o Others Market, By Product: o Kits and Assays o Reagents o Instruments Market, By End-User: o Hospital o Clinics o Diagnostic Laboratories o Others Market, By Region: o North America - United States - Mexico - Canada o Europe - Germany - France - United Kingdom - Italy - Spain o Asia-Pacific - China - India - Japan - South Korea - Australia - Singapore o Middle East and Africa - South Africa - Saudi Arabia - UAE o South America - Brazil - Argentina - Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global autoimmune disease diagnostics market.

Available Customizations:

With the given market data, we offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Read the full report: https://www.reportlinker.com/p05916725/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: [emailprotected] US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

http://www.reportlinker.com

Go here to see the original:
Global Autoimmune Disease Diagnostics Market By Type, By Sex, By Age, By Factors, By Diagnosis, By Types of Treatment, By Product, By End-User, By...